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UNIT 4.22Stepwise Solid-Phase Synthesis of
Nucleopeptides
Modification of oligonucleotides by attachment of peptide chains has attracted consider-
able interest during the last few years. The covalent union of a peptide chain may have
beneficial effects on synthetic oligonucleotides (Tung and Stein, 2000), such as (1)
increasing their stability to exonucleases, (2) accelerating or enhancing hybridization to
their target sequences, and (3) facilitating their transport through cell membranes, which
is particularly important for antisense (or antigene) applications (Gait, 2003).
No rules are established to name and describe the different types of peptide-oligonu-
cleotide conjugates. The word nucleoprotein is used to describe both covalently and
noncovalently linked nucleic acid–protein complexes. Since in the former a phosphate
group links the 5′- or 3′-terminal hydroxyl group of a nucleic acid with the side-chain
hydroxyl group of serine, threonine, or tyrosine of a protein, phosphodiester-linked
peptide-oligonucleotide conjugates have often been denoted as nucleopeptides (Schat-
tenkerk et al., 1984; Robles et al., 1991; Waldmann and Gabold, 1997). Some authors,
however, have used the term nucleopeptide to refer to other types of conjugates (UNIT 4.5;
McMinn and Greenberg, 1999), and still others have referred to nucleopeptides as
peptide-oligonucleotide conjugates (see below; Stetsenko et al., 2002).
This unit describes stepwise solid-phase methods to obtain nucleopeptides containing
2′-deoxynucleosides and any of the proteinogenic amino acids, including the trifunctional
ones. The procedures reported here are also suitable for the preparation of other peptide-
oligonucleotide conjugates, since most of the critical points of the procedures are related
to the presence of purine nucleosides and some trifunctional amino acids in the target
molecule. Methods for synthesis of the desired support-bound peptide (see Basic Protocol
1) are followed by methods for preparing the solid support (see Support Protocol 1) and
several protected amino acids that are not commercially available (see Support Protocols
2 to 5). This is followed by extension of the oligonucleotide and cleavage and deprotection
of the nucleopeptide (see Basic Protocol 2), and analysis, purification, and charac-
terization of the target molecule (see Basic Protocols 3 and 4). Additional methods are
given for reduction of nucleopeptides containing sulfoxide-protected methionine (see
Support Protocol 6) and deprotection and purification of cysteine-containing nucleopep-
tides (see Support Protocol 7).
STRATEGIC PLANNING
Synthesis Strategy
The synthesis of any type of peptide-oligonucleotide conjugate is a chemical challenge,
because two completely different chemical entities must be assembled in the same
molecule. Since the beginning of this work, the aim of the authors was to develop the
simplest possible methodology for the preparation of nucleopeptides. In this respect, it
was clear that the use of solid-phase chemistry would be one of the keys to simplifying
the overall procedure.
Both peptides and oligonucleotides are usually obtained by well-established solid-phase
procedures, but the two methodologies differ considerably in many aspects. First, the
coupling step is obviously different. In peptide synthesis, carboxylic acids have to be
activated to form amide bonds with the free amine groups immobilized on the solid
support, while elongation of oligonucleotide chains requires a phosphoric ester to be
formed between two hydroxyl groups. Second, the protecting groups required at every
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step to mask the appropriate functionalities—and, consequently, the treatments necessary
for their removal—are also quite different.
Peptide chains are commonly obtained either by using groups that are labile to acids of
different strength (the so-called Boc/benzyl strategy) or by using a combination of
base-labile temporary α-amine-protecting groups and acid-labile permanent side-chain-
protecting groups (Fmoc/tBu strategy). As most readers know, oligonucleotide synthesis
combines the use of very mild acidic conditions to eliminate the temporary protecting
groups (in order to prevent depurination) with that of a basic ammonia treatment to remove
the permanent protecting groups (see UNIT 2.1). This scenario illustrates that the two
methodologies cannot easily be made compatible, as the standard final treatment in
peptide synthesis is a reaction in acidic conditions, under which an oligonucleotide chain
would not survive. Another point of concern is the stability of the [hydroxylated amino
acid]-nucleoside phosphodiester linkage, which can undergo a β-elimination process that
degrades the target molecule (Shabarova, 1970). Figure 4.22.1 shows the β-elimination
side reaction that may affect nucleopeptides (depurination is shown in Figure 2.1.8).
The synthesis protocol described here is a stepwise approach (Fig. 4.22.2). It has been
optimized so that the methodology is accessible to groups of nonspecialists in the field
and, whenever possible, is compatible with commercially available synthons.
Taking into account that peptide chains are normally elongated from the C to N terminus
and oligonucleotides from the 3′ to 5′ terminus (although reverse elongation is also
possible), elongation of the oligonucleotide chain at the side-chain hydroxyl of a resin-
linked peptide seemed the best alternative. First, this allows greater stability, as the peptide
is more robust than the oligonucleotide, particularly to acidic treatments. Second, this
allows the linking amino acid to be placed at any position in the peptide chain. Stepwise
assembly of the peptide moiety on a resin-linked oligonucleotide would only yield
nucleopeptides with the linking amino acid at the C terminus. Moreover, difficulties in
coupling amino acids onto resin-linked oligonucleotides have in some cases been reported
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Figure 4.22.1 Base-promoted cleavage of nucleopeptides with serine- or threonine-nucleoside
phosphodiester bonds.



































1.  20% piperidine/DMF
2.  H-HMFS-OH, DCC
1.  Boc-Ala-OH, DCC, DMAP
2.  Ac2O, pyr
+A
Figure 4.22.2 (continues on next page) Stepwise solid-phase synthesis of nucleopeptide Ac-Lys-
Trp-Lys-Hse(p3édGCATCG)-Ala-OH. (A) Preparation of the [C-terminal amino acid]-resin includes
coupling of an IRAA and an HMFS linker (handle) to the resin (see Support Protocol 1), followed
by coupling of the C-terminal amino acid (see Basic Protocol 1). (B) Peptide assembly (see Basic
Protocol 1) followed by oligonucleotide assembly and final deprotection (see Basic Protocol 2) yield
the crude target nucleopeptide. 1HOBt must be added to couple homoserine. Bases: B1 and B6,
N2-isobutyrylguanin-9-yl; B2 and B5, N
4-benzoylcytosin-1-yl; B3, N
6-benzoyladenin-9-yl; B4, thymin-
1-yl. Other abbreviations: aa, amino acid; Boc, tert-butoxycarbonyl; CNE, 2-cyanoethyl; DCC,
N,N′-dicyclohexylcarbodiimide; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; DMAP,
4-(N,N-dimethylamino)pyridine; DMF, N,N-dimethylformamide; DMTr, 4,4′-dimethoxytrityl; dN, 2′-
deoxyribonucleoside; Fmoc, 9-fluorenylmethoxycarbonyl; For, formyl; HOBt, 1-hydroxybenzotria-
zole; Hse, homoserine; H-HMFS-OH, N-[9-(hydroxymethyl)-2-fluorenyl]succinamic acid; IRAA,
internal reference amino acid; MBHA, p-methylbenzhydrylamine; NMI, N-methylimidazole; PS,
polystyrene-co-1%-divinylbenzene; pyr, pyridine; TCA, trichloroacetic acid; Tfa, trifluoroacetyl; TFA,
trifluoroacetic acid.






Oligonucleotide assembly onto a resin-linked peptide is usually carried out with 3′-phos-
phoramidite nucleoside derivatives, which links the peptide to the 3′ end of the oligonu-
cleotide. Substitution of 5′-phosphoramidites for the 3′-derivatives allows
peptide-5′-oligonucleotides to be obtained.
Choice of Protecting Groups
The main concern in the overall process is the choice of protecting groups. They must be
chosen so that the integrity of the target molecule is not affected by the final deprotection
conditions. This means, as previously stated, avoiding the use of harsh acidic and basic
treatments. Peptide assembly is compatible with the use of Nα-Boc-protected amino acids,
and, although they are often commercially available with acid-labile side-chain-protect-
ing groups, some derivatives with base-labile groups at the side chain are available. The
only problem, then, is the peptide-oligonucleotide phosphate union, which in some cases
can be particularly labile to bases. Since the data available at the outset of this work
suggested that basic treatments could to some extent (though not completely) degrade
nucleopeptides in which serine or threonine are the linking amino acids, it seemed possible
to choose permanent protecting groups such that their removal under basic conditions



















1.  30% TFA/DCM
2.  5% DIPEA/DCM
3.  Boc-aa-OH, DCC 1
4.  Ac2O
1.  DMTr-dN-O-P(OCNE)NiPr2, tetrazole
2.  capping (Ac2O, NMI)
3.  oxidation (1 M t-BuOOH)















All of the permanent protecting groups used in this procedure are shown in Table 4.22.1
and Fig. 4.22.3, and are discussed further below. They are chosen to be labile to the
standard oligonucleotide-deprotecting reagent, aqueous ammonia. This is fully compat-
ible with tyrosine nucleopeptides. Furthermore, if the nucleopeptide is not to reproduce
the linking site of a naturally occurring nucleoprotein, the natural nonproteinogenic amino
acid homoserine can be used as the linking residue (Fig. 4.22.2B), as first described in
1997 (Beltrán et al., 1997; Robles et al., 1997). No β-elimination can take place in this
case, since the phosphate group is linked to the γ-carbon of the amino acid. Note, however,
that the great tendency of homoserine to form γ-lactones precludes its use as the
C-terminal amino acid. For the synthesis of serine and threonine nucleopeptides, the
mildest final deprotection conditions must be used (see below).
Table 4.22.1 Recommended Permanent Protection Schemea,b








Asp, Glu OFm OFm
Asn, Gln — —c
Lys Fmoc Tfa
Arg (Fmoc)2 (Fmoc)2
Hisd H, Tos (Dnp) Tos (Dnp)






Cleavage conditions NH3/dioxane, room
temperatureh
NH3/dioxane, 55°C or (i)
TBAF, (ii) NH3/dioxane,
55°C
aRefer to Figure 4.22.3 for abbreviations and structures of the amino acid protecting groups. Dash
indicates no protecting group needed.
bAbbreviations for base protection: Ac, acetyl; Bz, benzoyl; Dmf, dimethylaminomethylene; i-Bu,
isobutyryl.
cHomoserine or tyrosine nucleopeptides that do not contain Asn, Gln, or Cys.
dHistidine is introduced protected with the tosyl (Tos) group, which is removed prior to oligonucleotide
elongation. Dnp-protected histidine must be used if His is placed at the C-terminal position. Dnp
removal requires overnight ammonia/dioxane treatment at room temperature. For further comments
on histidine protection, see Strategic Planning.
eThese residues are incorporated unprotected when they are the linking amino acid and protected as
indicated when they are not.
fThe crude nucleopeptide must be treated with N-methylmercaptoacetamide to reduce the sulfoxide to
a thioether.
gDTT must be added to the ammonia/dioxane solution to simultaneously remove the thiol protecting
group.
hThese very mild deprotection conditions must be used if serine or threonine are the linking residues
or if the nucleopeptide contains asparagine and cysteine. In other circumstances, strongest deprotection
treatments may be allowed (see Strategic Planning, discussion of final deprotection conditions).







Copolymers of styrene and 1% divinylbenzene are classic supports for peptide synthesis,
while controlled-pore glass beads are typically used for the preparation of oligonu-
cleotides. Polyethyleneglycol-polystyrene copolymers have been used in the synthesis of
both types of molecules. In the authors’ hands, the best results have been achieved using
the polystyrene-1%-divinylbenzene copolymer (Robles et al., 1999). The authors use the
p-methylbenzhydrylamine resin (see Fig. 4.22.2A), but aminomethylpolystyrene should
also work.
Internal Reference Amino Acid
Incorporation of an internal reference amino acid (IRAA; Fig. 4.22.2A) has two benefits.
First, it allows one to adjust the substitution degree of the solid support to the desired
level. Previous work (Montserrat et al., 1994) showed that substitution degrees of >0.20
mmol/g are not suitable for oligonucleotide synthesis, and that amine-functionalized
polystyrene resins generally have higher loadings. The loading can be reduced by
incompletely incorporating one amino acid and capping the unreacted amines. Use of
Nα-Fmoc derivatives has the advantage that deprotection of an aliquot with piperidine and
spectrophotometric quantitation of the resulting N-(9-fluorenylmethyl)piperidine easily
allows the degree of substitution to be calculated.
Amino acid Side chain Protected side chain
Structure of the
protecting groups
Asp, Glu (CH2)1-2 CO OH (CH2)1-2 CO O Fm
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Figure 4.22.3 Structures of the unprotected and protected side chains of the trifunctional amino acids, and structures of
the permanent protecting groups suitable for nucleopeptide synthesis. Abbreviations: Ac, acetyl; Dnp, 2,4-dinitrophenyl; Fm,
9-fluorenylmethyl; Fmoc, 9-fluorenylmethoxycarbonyl; For, formyl; Tfa, trifluoroacetyl; Tos, tosyl.






The second benefit of incorporation of an IRAA is that it allows some reaction yields to
be determined. On one hand, the yield of incorporation of the C-terminal amino acid can
be assessed by the ratio of C-terminal amino acid to IRAA obtained after acid hydrolysis
and amino acid analysis of an aliquot of resin. On the other hand, the comparison of the
peptide/IRAA ratio before and after cleavage allows one to determine the cleavage yield.
Obviously, the IRAA must be different from the nucleopeptide amino acids.
Handle
The handle permanently protects the carboxyl group of the C-terminal amino acid (Fig.
4.22.2A). It is a bifunctional molecule with one carboxyl and one hydroxyl group. The
former forms a stable amide bond with the IRAA and the latter an ester with the C-terminal
amino acid. Cleavage of the nucleopeptide-resin ester linkage requires basic conditions
to which the nucleopeptide remains stable.
The authors have tested two different handles: 2-nitrophenyl ester (NPE; Eritja et al.,
1991) and fluorenylmethyl ester (HMFS; Albericio et al., 2001). The fluorenylmethyl
ester is more labile than the 2-nitrophenyl ester, and is therefore the most adequate to
synthesize serine and threonine nucleopeptides. Since mild cleavage conditions are
required to prevent peptide-related side reactions (as well as to prevent base-promoted
peptide-oligonucleotide cleavage, see below), the HMFS handle is now routinely used in
the authors’ laboratory and is the recommended option.
Protecting Groups for the Peptide Chain
Peptide assembly is carried out using the tert-butoxycarbonyl (Boc) group to temporarily
protect the α-amino function. Removal of this protecting group requires treatment with
30% to 40% trifluoroacetic acid (TFA) in dichloromethane, which is fully compatible
with the base-labile ester that links the C-terminal amino acid to the resin. Protection of
the trifunctional amino acid side chains is discussed for each type of residue (see Table
4.22.1 and Fig. 4.22.3).
Aspartic and glutamic acids
The β- and γ-carboxyl groups of these residues are protected as 9-fluorenylmethyl (Fm)
esters, which have the same lability as the nucleopeptide-HMFS linkage. Boc-Asp(OFm)-
OH and Boc-Glu(OFm)-OH are commercially available. Side reactions associated with
aspartimide formation in some peptide sequences (most notably, Asp-Gly) may take place
during the final deprotection treatment (Jeyaraj et al., 2002).
Asparagine and glutamine
The primary carboxamides of these residues’ side chains can be left unprotected.
Phosphitylation of these groups by tetrazole-activated phosphoramidites has been shown
to be virtually nil (Garcia de la Torre et al., 1999; Debéthune et al., 2002a), so there is
very little risk of obtaining branched nucleopeptides. Final deprotection must be carried
out using the mildest conditions (see below) to prevent side reactions associated with the
55°C ammonia treatment of asparagine-containing nucleopeptides (Debéthune et al.,
2002a).
Lysine
The ε-amino function can be protected with either the trifluoroacetyl (Tfa) or 9-fluorenyl-
methoxycarbonyl (Fmoc) groups (Robles et al., 1999). Tfa can only be removed by
ammonia treatment at 55°C, while milder basic treatments eliminate the Fmoc groups.
Both derivatives are commercially available.







The easiest way to prevent reactions at the guanidinium group is to keep it protonated.
Washing with solutions of weak proton donors (e.g., 1-hydroxybenzotriazole, tetrazole)
prior to amino acid or nucleoside coupling is required to ensure that the strongly basic
guanidinium group is not free. Nevertheless, optimal results were achieved using the
Boc-Arg(Fmoc)2-OH derivative (Debéthune et al., 2002a). Boc-Arg-OH⋅HCl can be
purchased from commercial suppliers and the synthesis of Boc-Arg(Fmoc)2-OH is
described in this unit (see Support Protocol 2).
Histidine
The imidazole ring must be protected during histidine incorporation to prevent racemi-
zation at the α-carbon. Two commercially available Boc-histidine derivatives can be used
for nucleopeptide synthesis; they are imidazole-protected using either the tosyl (Tos)
group or the 2,4-dinitrophenyl (Dnp) group (Beltrán et al., 1998). The tosyl group is labile
to nucleopeptide deprotection conditions and can also be removed by treatment with
1-hydroxybenzotriazole (HOBt; Fujii and Sakakibara, 1974). Since the best-quality crude
nucleopeptides were obtained when phosphoramidites were coupled onto histidine-un-
protected peptide-resins, it is recommended that the experimenter (1) use Boc-His(Tos)-
OH for peptide synthesis, (2) treat with HOBt to deprotect the imidazole ring (if no HOBt
has been used at any amino acid coupling step), and (3) proceed with the oligonucleotide
assembly.
In nucleopeptides with histidine at the C terminus, the imidazole ring should be kept
protected throughout the entire synthesis process. This is best achieved using the Dnp
group. Undesired detachment of the growing nucleopeptide chains from the resin, which
can slowly take place if the imidazole ring is unprotected, can thus be avoided. The Dnp
group is labile to fluoride treatment (see below) as well as ammonia treatment at either
room temperature (overnight) or 55°C (6 hr).
Serine, threonine, and tyrosine
The side-chain hydroxyl of these amino acids (when they are not used as the linking
residue) are protected with the acetyl (Ac) group (Fig. 4.22.3), which can be removed in
the mildest final deprotection conditions. Boc-Ser(Ac)-OH and Boc-Tyr(Ac)-OH can be
purchased from commercial suppliers. The preparation of Boc-Thr(Ac)-OH is described
in this unit (see Support Protocol 5).
Tryptophan
Best results are achieved using the commercially available indole-protected derivative
Boc-Trp(For)-OH, in which the indole ring is N-formylated (Robles et al., 1999). The
formyl group can be removed by ammonia treatment at room temperature.
Methionine
The sulfide function of the methionine side chain can be alkylated during peptide
elongation, and is oxidized at the nucleotide incorporation cycles. To prevent side
reactions, the commercially available sulfoxide derivative Boc-Met(O)-OH is recom-
mended (Marchán et al., 2000). After nucleopeptide synthesis and deprotection, the
sulfoxide is reduced to a sulfide by reaction with N-methylmercaptoacetamide (see
Support Protocol 6).







Boc-Cys(S-tBu)-OH (where S-tBu is tert-butylthio), in which the thiol group has been
transformed into a sterically hindered disulfide, allows cysteine-containing nucleopep-
tides to be obtained (Debéthune et al., 2002a). Care must be taken during the final
deprotection step to avoid loss of HS-S-tBu by β-elimination. The target product is safely
obtained if the final deprotection is carried out by treating the nucleopeptide-resin with
ammonia at room temperature in the presence of 1,4-dithiothreitol (see Support Protocol
7). Boc-Cys(S-tBu)-OH can be easily obtained from the commercially available H-Cys(S-
tBu)-OH derivative (see Support Protocol 3).
Linking Amino Acid
Serine, threonine, and tyrosine are introduced as Nα-Boc derivatives with the side-chain
hydroxyl unprotected. No acylation of the free hydroxyl has been detected if the sub-
sequent amino acids are incorporated using N,N′-dicyclohexylcarbodiimide (DCC) to
activate the carboxyl group. Nα-Boc-protected homoserine derivatives are not available
from commercial suppliers. The synthesis of the required compound is described here
(see Support Protocol 4; Beltrán et al., 1997). This derivative, which is obtained as the
triethylammonium salt Boc-Hse(DMTr)-O– HTEA+, will not couple onto the growing
peptide chain unless a proton donor is added to the carbodiimide activator; therefore, this
coupling is performed in the presence of HOBt.
Peptide Assembly
Peptide synthesis is carried out manually in polypropylene syringes fitted with polyeth-
ylene disks. An automatic synthesizer can also be used. As stated above, carbodiimides
(N,N′-dicyclohexylcarbodiimide or N,N′-diisopropylcarbodiimide) are used to activate
the carboxyl group of the incoming amino acid. 4-Dimethylaminopyridine must be added
during the incorporation of the first (C-terminal) amino acid to achieve good esterification
yields. Addition of HOBt is required to prevent side reactions during the activation and
incorporation of asparagine, glutamine, and unprotected arginine, and to couple the
homoserine derivative (HOBt can be replaced by tetrazole in this case).
Some peptide sequences are particularly prone to form diketopiperazines (Pro-aa or
aa-Pro, where aa is any amino acid, are typical examples; Gisin and Merrifield, 1972).
This means that the free amine group of a dipeptide reacts with the resin-linked terminal
carboxyl, releasing a cyclic dipeptide (diketopiperazine) and liberating free hydroxyl
groups on the solid support. This unwanted side reaction can be minimized (Gairí et al.,
1990) by reacting the third amino acid with the trifluoroacetate salt of the dipeptide-resin
in the presence of a strong carboxyl activator reagent (PyAOP, 7-aza-benzotriazol-1-yl-
oxytripyrrolidinephosphonium hexafluorophosphate) and an excess of N,N-diiso-
propylethylamine.
Protecting Groups for the Oligonucleotide Moiety
Standard DMTr and 2-cyanoethyl groups are used for temporary protection of the
5′-hydroxyl (or 3′-hydroxyl, if 5′-phosphoramidites are used) and for permanent protec-
tion of the phosphates, respectively. For the preparation of tyrosine and homoserine
nucleopeptides, and if no side reaction–originating amino acids (Asn, Asp, or Cys) are
present, standard nucleobase-protecting groups can be used: benzoyl (Bz) for A and C,
and isobutyryl (i-Bu) for G. If base-labile nucleopeptides are to be obtained and/or the
hybrid contains “delicate” amino acids, more labile nucleobase-protecting groups must
be used. C is then protected with the acetyl (Ac) group, and the exocyclic amine of G is
protected as formamidine with the dimethylaminomethylene group (Dmf). The structures
of all of these protecting groups appear in Figures 2.1.7 and 2.1.10.







The oligonucleotide is assembled on an automatic DNA synthesizer (ABI 380B). Small
modifications of the standard synthesis cycle are introduced to optimize performance with
polystyrene resins (Bardella et al., 1990). The authors usually replace the standard iodine
oxidation reagent with a 1 M solution of t-BuOOH, which facilitates washing of the resin
after the oxidation step. Use of this reagent is absolutely mandatory when the nucleopep-
tide contains tyrosine or unprotected tryptophan, to prevent iodination of their aromatic
side chains. Nucleopeptides with phosphorothioate internucleoside linkages have been
obtained using the Beaucage reagent for the sulfurization step (Robles et al., 1999).
Final Deprotection Conditions
The polystyrene-divinylbenzene copolymer is hydrophobic and does not swell in aqueous
medium. Consequently, treatments of nucleopeptide-resins with ammonia are not carried
out using a 33% concentrated aqueous solution, but with a 1:1 (v/v) mixture of concen-
trated aqueous ammonia/dioxane.
To cleave [base-stable nucleopeptide]-resin bonds, a two-step procedure is recommended:
(1) treatment with tetrabutylammonium fluoride in anhydrous tetrahydrofuran, which
detaches the nucleopeptide from the resin and removes most amino acid–protecting
groups, and (2) treatment of the resulting filtrate with concentrated ammonia (or 1:1
ammonia/dioxane) to eliminate other remaining protecting groups. The authors have
obtained better cleavage yields with this procedure than with an overnight treatment of
the nucleopeptide-resin with ammonia at 55°C. The reaction with fluorides is a β-elimi-
nation process that yields the nucleopeptide with a C-terminal carboxylic acid function





















Figure 4.22.4 Mechanisms of cleavage of the [C-terminal amino acid]-resin ester linkage. (A)
Base-promoted β-elimination yields a C-terminal carboxylic acid function; (B) nucleophile-promoted
cleavage yields a C-terminal carboxamide.






The nucleopeptide-HMFS linkage can also be cleaved under milder conditions by
treatment with 1:1 ammonia/dioxane at room temperature. Although cleavage yields are
lower than if the reaction is carried out at 55°C, this is the only alternative if the target
nucleopeptide has serine or threonine as the linking residue, or if it contains amino acids
(or peptide sequences) which are prone to give side reactions under these conditions (see
above).
An additional point of concern when the nucleopeptide-resin is treated directly with
ammonia is that cleavage can take place either by β-elimination (Fig. 4.22.4A), which
affords the nucleopeptide acid, or by nucleophilic attack of ammonia at the ester bond
between the C-terminal amino acid and the HMFS handle (Fig. 4.22.4B). Nucleopeptides
are then obtained as C-terminal carboxamides. Acid/carboxamide mixtures (in which the
acid is the main component) are always obtained when glycine is the C-terminal amino
acid (Debéthune et al., 2002a). The amount of amide is virtually nil when other residues
occupy the C-terminal position.
Summary
As a general rule, the authors recommend assembling the nucleopeptide using a set of
permanent protecting groups that can be removed using the mildest deprotection condi-
tions, but little or no care has to be taken if tyrosine or homoserine is the linking amino
acid and the nucleopeptide does not include “delicate” amino acids.
However, even under the mildest possible final deprotection conditions, degradation of
serine nucleopeptides by base-mediated cleavage of the serine-nucleoside phosphodiester
bond can take place in some cases (Debéthune et al., 2002a). The data available indicate
that this is a sequence-dependent reaction whose extent cannot as yet be predicted.
From an operational point of view, the preparation of a nucleopeptide requires an
adequately functionalized solid support and suitably protected amino acid and nucleoside
derivatives. Access to an HPLC, a UV spectrophotometer, an electrospray or MALDI-
TOF mass spectrometer, and an amino acid analyzer is required. Denaturing polyacryl-
amide gel electrophoresis (PAGE) facilities may also be necessary.
BASIC
PROTOCOL 1
STEPWISE MANUAL SOLID-PHASE SYNTHESIS OF THE PEPTIDE
In this protocol, the C-terminal amino acid is first coupled to a solid support that has
already been coupled with the internal reference amino acid (IRAA) and the HMFS linker
(see Support Protocol 1 and Fig. 4.22.2A). Incorporation of the terminal amino acid is
compared to the IRAA by amino acid analysis. After acylation of unreacted HMFS
hydroxyl groups, the subsequent amino acids are added until the final support-bound
peptide has been synthesized (Fig. 4.22.2B).
During synthesis, each coupling is monitored by a ninhydrin or chloranil test. The
ninhydrin test (Kaiser et al., 1970) is only reliable for primary amines. For a qualitative
coupling assay in the case of proline, the chloranil test (Christensen, 1979) should be used
to assay for secondary amines.
In general, the support-bound peptide (step 28) can be used directly for elongation of the
oligonucleotide chain (see Basic Protocol 2). In some cases, especially with long peptides,
analysis of the deprotected crude peptide by HPLC and mass spectrometry techniques
(steps 29 to 41) is recommended to ensure peptide homogeneity before oligonucleotide
elongation.







Derivatized p-methylbenzhydrylamine solid support (H-HMFS-IRAA-MBHA-PS;
see Support Protocol 1)
Dichloromethane (DCM; peptide synthesis grade)
N,N-Dimethylformamide (DMF; peptide synthesis grade)
t-Butoxycarbonyl-protected amino acids (Boc-aa-OH):
 Ala, Arg⋅HCl, Asn, Asp(OFm), Gln, Glu(OFm), Gly, His(Dnp), His(Tos), Ile,  
 Leu, Lys(Fmoc), Lys(Tfa), Met(O), Phe, Pro, Ser, Ser(Ac), Thr, Trp(For), Tyr,
 Tyr(Ac), and Val (Novabiochem, Bachem, Neosystem)
 Boc-Arg(Fmoc)2-OH (see Support Protocol 2)
 Boc-Cys(S-tBu)-OH (see Support Protocol 3)
 Boc-Hse(DMTr)-O–HNEt3
+ (see Support Protocol 4)
 Boc-Thr(Ac)-OH (see Support Protocol 5)
N,N′-Dicyclohexylcarbodiimide (DCC) or N,N′-diisopropylcarbodiimide (DiPC)
4-Dimethylaminopyridine (DMAP)
Methanol (MeOH; HPLC grade)
Concentrated HCl, analytical grade
Propionic acid
Phenol, crystalline
3 M aqueous p-toluenesulfonic acid containing 0.2% tryptamine




30% (v/v) trifluoroacetic acid (TFA; peptide synthesis grade) in DCM
5% (v/v) N,N-diisopropylethylamine (DIPEA) in DCM
1-Hydroxybentotriazole (HOBt; for coupling unprotected Arg, Asn, Gln, Hse)
0.5 M HOBt in DCM (for coupling unprotected Arg)
(Azabenzotriazole-1-yl-oxy-tris-pyrrolidino)phosphonium hexafluorophosphate
(PyAOP; for coupling any aa onto Pro)
N,N-Diisopropylethylamine (DIPEA)
Ethyl acetate (EtOAc)
1 M sulfuric acid
Sodium sulfate (Na2SO4), anhydrous
Ninhydrin reagents A and B (see recipes)
Saturated chloranil solution: ∼0.75 g of 2,3,5,6-tetrachloro-1,4-benzoquinone in 25
mL toluene
Acetone
Peroxide-free dioxane (see recipe)
1 M 1,4-dithiothreitol (DTT) in peroxide-free dioxane (for S-tBu-protected Cys)
32% (v/v) ammonium hydroxide (store at 4°C)
HPLC mobile phase A: 0.045% TFA in water (HPLC grade)
HPLC mobile phase B: 0.036% TFA in acetonitrile (HPLC grade)
α-Cyano-4-hydroxycinnamic acid (CHA) or dihydroxybenzoic acid (DHB) matrix
0.1% TFA in 1:1 (v/v) acetonitrile/water (HPLC grade)
2- to 10-mL disposable polypropylene syringes with porous polyethylene discs




Pyrex tubes for amino acid analyses
Methane/oxygen flame






110° and 155°C heating block
Rotary evaporator equipped with a water aspirator or vacuum pump (use aspirator
unless pump is indicated)
0.45-µm nylon filters
Automatic amino acid analyzer (Beckman System 6300)
25-mL separatory funnel
Filter paper
25- and 50-mL round-bottom flasks
Small glass tubes for ninhydrin or chloranil tests
4-mL screw-cap pressure tubes, O-ring seal preferred
Additional reagents for HPLC and MALDI-TOF-MS (see Basic Protocol 3 and
Chapter 10)
CAUTION: Trifluoroacetic acid is a very corrosive acid. Breathing the vapors is very
harmful and it is possible to be quickly overcome by them. Always manipulate with
extreme caution in a well-ventilated fume hood and wear appropriate protective clothing.
Prepare syringe with solid support for peptide synthesis
1. Transfer an accurately weighed amount of H-HMFS-IRAA-MBHA-PS solid support
for a 50-µmol synthesis into a 5- to 10-mL polypropylene syringe fitted with a porous
polyethylene disc and equipped with a Teflon two-way stop cock.
2. Place the syringe on a vacuum filtration system.
Incorporate C-terminal amino acid onto support
3. Wash the solid support using three 30-sec washes each of DCM, DMF, and then DCM
again.
For washes and for deprotection and neutralization treatments, a solvent volume of one or
two times the volume of resin is recommended. For coupling, it is important to keep the
reaction mixture as concentrated as possible. Coupling reactions must therefore be carried
out in the minimum amount of solvent required to swell the resin and allow stirring.
It is important to handle the polystyrene resin carefully to avoid mechanical degradation
of the solid matrix. In all steps that require mixing, the resin should be stirred very carefully
with a Teflon stir rod.
4. Weigh out the required amount of Boc-aa-OH (10 eq), DCC (10 eq), and DMAP (0.5
eq), and dissolve the mixture in a minimal volume of 1:1 (v/v) DCM/DMF.
DiPC can replace DCC in all reactions described in this protocol and in the Support
Protocols. The urea derivative formed after activation of the carboxyl group is more soluble
in organic solvents.
The esterification conditions employed for the incorporation of the C-terminal amino acid
may cause some racemization, especially with amino acids such as unprotected histidine.
In order to avoid this side reaction, glycine has been selected in most cases as the
C-terminal amino acid. However, some problems may arise during the ammonium hydrox-
ide deprotection (see Strategic Planning for more details).
5. Add the reaction mixture to the solid support and let stand 1.5 hr, occasionally stirring
with a Teflon stir rod.
6. Wash the solid support successively with three 30-sec washes of DMF and three
30-sec washes of DCM.
7. Repeat steps 4 to 6 using 5 eq Boc-aa-OH, 5 eq DCC, and 0.25 eq DMAP and a
reaction time of 1 hr.
8. Wash the solid support three times for 30 sec with MeOH and dry in a desiccator.






Determine C-terminal amino acid incorporation: General procedure for amino acid
analysis
9. Withdraw a 5- to 10-mg aliquot of dry resin and place it in a Pyrex tube.
10. Add 300 µl of 1:1 (v/v) concentrated HCl/propionic acid to the resin.
When tyrosine is present, add a phenol crystal to the mixture to prevent decomposition of
this amino acid during acid hydrolysis.
Some amino acids, such as cysteine, homoserine, serine, threonine, and tryptophan, are
partially or completely destroyed during acid hydrolysis. Arginine is partially converted to
ornithine, and asparagine and glutamine to aspartic and glutamic acids, respectively. When
the determination of some of these particular residues is necessary, enzymatic digestion
must be carried out (see Basic Protocol 3, step 51). When determining tryptophan
incorporation, hydrolysis must be carried out with a 3 M p-toluenesulfonic acid solution
containing 0.2% of 3-(2-aminoethyl)indole (tryptamine), for 12 hr at 110°C in a vacuum-
sealed Pyrex tube.
11. Close the Pyrex tube hermetically using a methane/oxygen flame and heat 1.5 hr in
a 155°C heating block.
12. Cool to room temperature, open the Pyrex tube, and evaporate the acidic mixture to
dryness in a rotary evaporator equipped with a vacuum pump.
CAUTION: Always wear gloves and glasses and work in a well-ventilated fume hood when
carrying out these operations. Be careful when closing and opening the tube.
13. Redissolve the dry residue in 500 µL of 0.06 M citrate buffer, pH 2, and filter the
resulting solution through a 0.45-µm nylon filter. Inject in an automatic amino acid
analyzer.
The amount of sample necessary for carrying out the amino acid analysis depends on the
analyzer. For some analyzers, 5 nmol amino acid is optimal. In that case, injection of 50
L of the resulting solution will give 2 to 10 nmol of each residue.
Prior to analyzing the sample, a standard that contains all 20 natural amino acids is
analyzed to calculate a response factor for each residue under the analysis conditions
employed. The response factors are used to calculate the amount of each residue in the
sample.
14. Compare incorporation of the C-terminal amino acid to incorporation of the IRAA.
If (C-terminal amino acid/IRAA) < 0.9, repeat steps 7 to 13. If 0.9 ≤ (C-terminal
amino acid/IRAA) ≤ 1, proceed with step 15.
In general, a nearly quantitative incorporation is achieved.
Acylate unreacted hydroxyl groups of HMFS linker
15. Add the required amount of acetic anhydride or benzoyl chloride (10 eq), pyridine
(10 eq), and DCM to the solid support and let stand 10 min with occasional stirring
using a Teflon rod.
As for the coupling steps, a minimum volume of DCM is used for this step. The volume
should be sufficient to swell the resin and allow stirring with the Teflon rod.
16. Wash the resin three times for 30 sec with DCM and repeat steps 15 and 16 to ensure
that all unreacted hydroxyl groups are capped.
17. Wash the resin successively with three 30-sec washes each of DMF, DCM, and
MeOH. Dry directly on a vacuum filtration system.






Incorporate subsequent amino acids
18. Add the required volume of 30% (v/v) TFA in DCM (one or two times the resin
volume) and let stand 5 min with occasional stirring using a Teflon rod.
19. Wash with DCM, add an equal volume of 30% TFA in DCM, and let stand 25 min
with occasional stirring.
20. Wash thoroughly with DCM, then wash four times for 60 sec with 5% (v/v) DIPEA
in DCM, and five times for 30 sec with DCM.
21. Weigh out the required amount of Boc-aa-OH (3 eq) and DCC (3 eq), and dissolve
the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF. Add to the solid support
and let stand 1.5 hr with occasional stirring using a Teflon rod. Modify as necessary
for the following amino acid–specific conditions.
When coupling arginine with the side chain protonated, weigh out the required amount of
Boc-Arg-OH⋅HCl⋅2H2O (3 eq), DCC (3 eq), and HOBt (6 eq), and dissolve the mixture in
the minimum amount of 1:1 (v/v) DCM/DMF. To avoid undesired side reactions, wash the
resin four times for 60 sec with 0.5 M HOBt in DCM between steps 20 and 21.
For asparagine or glutamine, weigh out the required amount of Boc-Asn-OH or Boc-Gln-
OH (3 eq), DCC (3 eq), and HOBt (3 eq), dissolve in the minimum quantity of 1:1 (v/v)
DCM/DMF, and let stand 10 min at 0°C before adding it to the resin.
When coupling the second amino acid onto Pro-resin, skip the neutralization step with 5%
(v/v) DIPEA in DCM (step 20), weigh out the required amount of Boc-aa-OH (5 eq) and
PyAOP (5 eq), dissolve the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF, and
add it to the resin. Then add 10 eq DIPEA to the resin and let stand for 1.5 hr, stirring
occasionally with a Teflon rod.
An acidic additive is necessary for the incorporation of the triethylammonium salt of the
homoserine derivative. Weigh out the required amount of Boc-Hse(DMTr)-O–HNEt3
+ (3
eq), DCC (3 eq), and HOBt (3 eq), and dissolve the mixture in the minimum quantity of
1:1 (v/v) DCM/DMF. After incorporation onto the support, elimination of the tert-butoxy-
carbonyl group with trifluoroacetic acid removes the DMTr group, so it is possible to
quantify the coupling yield by quantitating the released DMTr cation (see Basic Protocol
2, step 11).
When using Boc-Thr(Ac)-O–DCHA+, a workup is necessary to isolate the protected amino
acid in the neutral species. Suspend Boc-Thr(Ac)-O–DCHA+ in EtOAc (∼5 mL/mmol amino
acid) and transfer to a 25-mL separatory funnel. Add the same volume of 1 M sulfuric acid.
Shake to achieve complete dissolution of the amino acid derivative. Separate the organic
layer, and extract the aqueous phase with more EtOAc (twice with 5 mL). Dry the organic
layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals clump together upon
swirling. Gravity filter the resulting solution through filter paper into a 50-mL round-bot-
tom flask. Rinse the Na2SO4 crystals with 5 to 10 mL EtOAc. Remove the solvent under
reduced pressure (i.e., in a rotary evaporator) to yield a white solid. Perform several
co-evaporations with DCM to eliminate traces of EtOAc.
22. Wash the resin successively with three 30-sec washes of DMF, DCM, and MeOH.
Dry directly on a vacuum filtration system.
Assess amino acid coupling
23. Withdraw a 0.5- to 1-mg aliquot of dry resin and place it in a small glass tube.
24a. For primary amines: Add 3 drops of ninhydrin reagent A and 1 drop of ninhydrin
reagent B. Heat the tube 3 min in a 110°C heating block. Allow to cool to room
temperature. Assess color and proceed to step 25.
It is important to have good quality ninhydrin reagents in order to obtain a reliable result.
See Reagents and Solutions for more specific details. This test was developed for the
primary amines of amino acids and may not be reliable for other primary amines.






24b. For proline: Add 5 drops saturated chloranil solution and 20 drops acetone. Stir 5
min at room temperature. Assess color and proceed to step 25.
25a. For negative tests: If the reaction mixture is yellow (indicative of a successful amino
acid coupling), proceed with the incorporation of the next amino acid (step 26).
25b. For positive tests: If the reaction mixture is blue for ninhydrin or green-blue for
chloranil (indicative of the presence of free primary or secondary amines, respec-
tively), repeat the coupling of the amino acid using the same amounts and conditions
(steps 18 to 22) and then repeat the ninhydrin or chloranil test.
25c. For repeated positive tests: If a blue or green-blue color persists after a second
coupling of the amino acid, cap the unreacted amines by adding acetic anhydride
(10 eq), DIPEA (10 eq), and DMF to the solid support. Let stand 10 min, stirring
occasionally with a Teflon rod. Wash the resin sequentially using three 30-sec
washes each of DMF followed by DCM. Repeat the ninhydrin or chloranil test to
confirm that all unreacted amines are capped before proceeding with the incorpo-
ration of the next amino acid (step 26).
26. Perform incorporation of the second and subsequent amino acids (steps 18 to 22),
confirming the success of each coupling (steps 23 to 25) before proceeding to the
next.
Some minor modifications have to be introduced depending on the desired functional group
at the N-terminal position of the peptide. If the amino group has to be acylated, remove the
tert-butoxycarbonyl group and acylate by treating with acetic anhydride (3 eq) in DMF for
15 to 25 min. A longer treatment could cause undesired acetylation of the free side chain
of the hydroxylated amino acid. When a free N-terminal position is desired, incorporate
the last residue as an Fmoc-protected amino acid instead of a Boc derivative. The
fluorenylmethoxycarbonyl group will be removed during the final ammonium hydroxide
treatment. In some cases the tert-butoxycarbonyl group can be used to block the N-terminal
position of the peptide. If that is the case, no further modification is necessary to the
standard procedure because the Boc group is stable to the final ammonium hydroxide
treatment.
27. Once the final (N-terminal) amino acid has been successfully coupled, proceed with
the amino acid analysis as described in steps 9 to 13.
When an Fmoc-amino acid derivative is introduced at the N-terminal position of the
peptide, it is recommended to eliminate the Fmoc group before carrying out acid hydrolysis.
This is because the Fmoc group may not be completely removed during the acid hydrolysis
treatment, especially when it protects some sterically hindered residues such as isoleucine.
For removal of the Fmoc group, treat the resin aliquot with 20% (v/v) piperidine in DMF
as described below (see Support Protocol 1).
28. Calculate the relative ratio of the amino acids according to their peak areas and
response factors (see step 13).
If the peptide was correctly elongated, the ratio of residues will be close to the theoretical
value.
Perform cleavage and deprotection (optional)
29. Take a 5- to 10-mg aliquot of dry peptide-resin and place it in a 4-mL screw-cap
pressure tube, preferably with an O-ring seal.
30. Add 1 mL peroxide-free dioxane and 1 mL of 32% ammonium hydroxide solution,
screw the cap on tightly, and leave 6 hr at room temperature.
If the peptide sequence contains trifluoroacetyl-protected lysine, perform the deprotection
at 55°C for 12 to 15 hr. If it contains tert-butylthio-protected cysteine, use 1 mL of 1 M
1,4-dithiothreitol in dioxane and 1 mL of 32% ammonium hydroxide.






31. Filter through a 2-mL polypropylene disposable syringe with a polyethylene or cotton
filter and collect the solution in a 25-mL round-bottom flask.
32. Wash the pressure tube several times with MeOH and pass through the syringe.
With tert-butylthio-protected cysteine-containing peptides, removal of 1,4-dithiothreitol is
required prior to HPLC analysis. Dilute the crude sample to 2 mL by adding water and
wash three times with 2 mL EtOAc. Proceed with the aqueous phase.
33. Concentrate the combined solution under reduced pressure to a volume of ∼0.5 mL.
Dilute the deprotected crude peptide with 0.5 mL HPLC mobile phase B and take an
aliquot (10 to 50 µL) for HPLC analysis.
Analyze crude peptide by HPLC (optional)
34. Program the gradient system to start with 10% mobile phase B, increasing the
percentage of mobile phase B with time (Table 4.22.2).
Ensure that there is sufficient mobile phase to keep intakes covered throughout the run. For
more specific details about HPLC analysis, see Basic Protocol 3 and UNIT 10.5.
35. Set the UV detector wavelength at 220 nm. Equilibrate the HPLC system with the
starting mobile phase composition (10% mobile phase B) until a flat baseline is
achieved at this detection wavelength.
36. Inject the sample by programming the autosampler or by loading it into the sample
loop using the appropriate syringe. Elute the sample by starting the gradient. Record
the chromatogram.
Typically, small peptides will elute at ∼10 to 15 min under the recommended conditions
(Table 4.22.2). When long peptides are prepared, it is recommended to use a gradient from
10% to 70% or 80% mobile phase B over 30 min and then wash as usual.
Ammonium hydroxide treatment gives a mixture of the C-terminal carboxylic acid and
carboxamide peptides, which usually elute in this order. Some UV-absorbing compounds
are eluted at high acetonitrile percentages. These peaks are associated with handle-derived
products formed during ammonium hydroxide treatment.
Table 4.22.2 Typical Gradient and Mobile Phase for RP-HPLC of
Deprotected Crude Peptidea







aGradient conditions are based on a flow of 1 mL/min using a Kromasil reversed-phase
C18 column (5-µm-diameter spherical silica, 4.0 × 250 mm) at room temperature with a
45-min overall cycle. Mobile phase A: 0.045% trifluoroacetic acid (TFA) in water; mobile
phase B: 0.036% TFA in acetonitrile.
bPercentage is at elapsed time.






Analyze crude peptide by MALDI-TOF-MS (optional)
37. Weigh 10 mg matrix (CHA or DHB) and place in a 1.5-mL microcentrifuge tube.
A CHA matrix is recommended for small peptides (mol. wt. <500) and DHB for a wide
range of masses.
38. Add 1 mL of 0.1% TFA in 1:1 (v/v) acetonitrile/water to the matrix. Vortex 30 sec to
allow complete dissolution.
Optimal results are obtained when the highest-purity matrices are used. Matrix solutions
should be made fresh prior to use. Storage for more than 3 days is not recommended.
39. To a 0.5-mL microcentrifuge tube, add 1 µL peptide sample solution and 1 µL matrix
solution. Mix by withdrawing and expelling the solution ten times with the pipet.
40. Spot 1 µL solution on a MALDI-TOF sample plate and dry. To allow homogeneous
crystallization, do not disturb the spotted samples after they start to crystallize.
41. Perform peptide MALDI-TOF-MS analysis in positive mode.
SUPPORT
PROTOCOL 1
PREPARATION OF THE SOLID SUPPORT (H-HMFS-IRAA-MBHA-PS)
This protocol describes the coupling of the internal reference amino acid and handle to
the solid support used for nucleopeptide synthesis (see Fig. 4.22.2A).
Additional Materials (also see Basic Protocol 1)
p-Methylbenzhydrylamine resin: (α-amino-α-xylyl)-polystyrene reticulated with
1% divinylbenzene (f = 0.5 to 0.6 mmol/g; Novabiochem)
9-Fluorenylmethoxycarbonyl-protected internal reference amino acid (Fmoc-aa;
Novabiochem, Bachem, Neosystem)
20% (v/v) piperidine in DMF
N-[9-(Hydroxymethyl)-2-fluorenyl]succinamic acid (H-HMFS-OH; Alberico et
al., 2001)
2- and 10-mL polypropylene syringes fitted with polyethylene discs
Teflon two-way stopcocks
50-mL volumetric flasks
Double-beam UV spectrophotometer, calibrated, and quartz cuvettes
Wash solid support
1. Transfer an accurately weighed amount of p-methylbenzhydrylamine resin into a
polypropylene syringe fitted with a polyethylene disc (i.e., 250 mg of resin into a
10-mL syringe).
2. Place the syringe on a vacuum filtration system.
3. Wash the solid support with three 30-sec washes of DCM.
For general guidelines on volumes and handling resin, see Basic Protocol 1, step 3.
4. Add the required volume of 30% (v/v) trifluoroacetic acid in DCM and let stand 5
min, occasionally stirring with a Teflon rod.
5. Wash with DCM, add an equal volume of 30% (v/v) trifluoroacetic acid in DCM, and
let stand 25 min.
6. Wash sequentially as follows:
Three times for 30 sec with DCM
Four times for 60 sec with 5% (v/v) DIPEA in DCM
Five times for 30 sec with DCM.






Incorporate internal reference amino acid
7. Weigh out the required amount of Fmoc-aa (0.5 eq) and DCC (0.5 eq), and dissolve
the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF.
The internal reference amino acid must not be present in the target nucleopeptide sequence.
8. Add the reaction mixture to the solid support and let stand 25 min, stirring occasion-
ally with a Teflon rod.
Coupling time and amount of reactants are optimized to obtain a desired loading of ≤0.25
mmol/g. An increased coupling time will yield higher substitution degrees that are not
adequate for oligonucleotide elongation.
9. Wash the solid support sequentially using three 30-sec washes each of DMF followed
by DCM.
Determine loading
10. Withdraw a 10-mg aliquot of dry resin and place it in a 2-mL polypropylene syringe
fitted with a polyethylene disc and stopcock.
11. Add 1 mL of 20% (v/v) piperidine in DMF and let stand 3 min, occasionally stirring
with a Teflon rod.
12. Open the stopcock and collect the filtrate in a 50-mL volumetric flask. Wash three
times with 2 mL DCM and collect in the same flask.
13. Repeat the piperidine treatment for 7 min and wash again three times with DCM.
Collect these filtrates together with the previous ones, and dilute with DCM to the
50-mL mark.
Piperidine treatments quantitatively remove the fluorenylmethoxycarbonyl protecting
group. An N-(9-fluorenylmethyl)piperidine (Fmp) adduct is formed during this treatment.
Its molar extinction coefficient at 300 nm (ε300) is 7800. Its quantitation allows the loading
of the solid support to be determined.
14. Prepare a reference solution by adding 2 mL of 20% (v/v) piperidine in DMF to a
50-mL volumetric flask and diluting to the mark with DCM.
15. Measure the sample absorbance at 300 nm (A300) on a calibrated, double-beam UV
spectrophotometer using the above solution as a reference. If A300 >1, dilute sample
as necessary to achieve a value <1.
If using a single-beam spectrophotometer, a baseline should be run with a sample
containing the reference solution (blank).
16. Calculate the solid support loading (f) as:
where V is the total volume of the solution (in mL), ε is the molar extinction
coefficient of the Fmp adduct at 300 nm (7800 L/mol/cm), l the absorbance path of
the cuvette (in cm), and m is the amount of solid support (in mg).
17. If f ≈ 0.15 to 0.25 mmol/g, proceed according to step 18 with the entire support batch.















Acylate unreacted amine groups and remove Fmoc
18. Add the required amount of acetic anhydride (10 eq), DIPEA (10 eq), and DMF to
the solid support and let stand 10 min, stirring occasionally with a Teflon rod.
19. Wash the resin three times for 30 sec each with DCM and then repeat step 18. Perform
the ninhydrin test with 0.5 to 1 mg of resin (see Basic Protocol 1, step 24a) to be sure
that all unreacted amino groups are capped (solution should be yellow).
20. Wash the resin three times for 30 sec each with DMF, then DCM, and then MeOH.
Dry directly on the vacuum filtration system.
21. Add the required volume of 20% (v/v) piperidine in DMF and leave 3 min, stirring
occasionally with a Teflon rod.
22. Wash five times for 30 sec each with DCM and once again add the required volume
of 20% (v/v) piperidine in DMF. Let stand 10 min, stirring occasionally with a Teflon
rod.
23. Wash thoroughly three times for 30 sec each with DMF and then DCM. Dry directly
on the vacuum filtration system.
Incorporate handle
24. Weigh out the required amount of H-HMFS-OH (3 eq) and DCC (3 eq) and dissolve
the mixture in the minimum quantity of 1:1 (v/v) DCM/DMF.
The synthesis of N-[9-(hydroxymethyl)-2-fluorenyl]succinamic acid is carefully described
elsewhere (see Albericio et al., 2001).
25. Add the reaction mixture to the solid support and let stand for 4 to 5 hr, stirring
occasionally with a Teflon rod.
26. Wash the solid support successively (three times for 30 sec each) with DMF, then
DCM, and finally MeOH. Dry directly on the vacuum filtration system.
27. Withdraw a 0.5- to 1-mg aliquot of dry resin and carry out the ninhydrin test (see
Basic Protocol, step 24a). If the coupling is not complete (i.e., solution is blue, not




Fmoc protection of Boc-Arg-OH is shown in Figure 4.22.5.
Materials
N-(tert-Butoxycarbonyl)-L-arginine hydrochloride (Novabiochem)
Acetonitrile, anhydrous (see recipe)
9-Fluorenylmethyl chloroformate (Fmoc⋅Cl)
Argon (Ar), dry
Dichloromethane (DCM, anhydrous; see recipe) in a septum-sealed distillation
collection bulb
N,N-Diisopropylethylamine (DIPEA), anhydrous (see recipe)
Chlorotrimethylsilane
Dichloromethane (DCM; synthesis grade)




230- to 400-mesh silica gel






250-mL oven-dried round-bottom flask and rubber septum
Desiccator containing P2O5
Glass syringe and needle, oven dried
40°C heat block
250-mL separatory funnel
Gravity and vacuum filtration devices and filter paper
500-mL round-bottom flasks
2 × 5–cm silica-coated thin-layer chromatography (TLC) plates
254-nm UV light source
Rotary evaporator with a water aspirator
5 × 25–cm glass chromatography column with solvent reservoir bulb
Additional reagents and equipment for TLC (APPENDIX 3D), column
chromatography (APPENDIX 3E), NMR, IR, and mass spectrometry
Fmoc-protect Boc-Arg-OH
1. Place 1.0 g (3.04 mmol) of N-(tert-butoxycarbonyl)-L-arginine hydrochloride in a
250-mL oven-dried round-bottom flask.
2. Co-evaporate three times with anhydrous acetonitrile.
3. Weigh 2.4 g (9.28 mmol) of Fmoc⋅Cl and dry overnight under vacuum in a desiccator
containing P2O5.
4. Cap the flask with a rubber septum and purge the flask with dry Ar.
5. Withdraw anhydrous DCM from a septum-sealed distillation collection bulb using
an oven-dried glass syringe and needle. Add 25 mL DCM to the purged flask with
magnetic stirring.
6. Add 1.6 mL (9.4 mmol) anhydrous DIPEA and slowly add 1.5 mL (11.9 mmol)
chlorotrimethylsilane.
7. Stir the reaction mixture 90 min at 40°C.
The original suspension slowly becomes a solution.
8. Cool in an ice bath. Dissolve 2.4 g (9.28 mmol) Fmoc⋅Cl in a minimal amount of dry
DCM. Add 1.6 mL DIPEA and the Fmoc⋅Cl to the cooled reaction.
9. Stir the mixture 20 min in the ice bath and then 6.5 hr at room temperature.









1.  TMS⋅Cl, DIPEA
2.   Fmoc-Cl
DCM
+
Figure 4.22.5 Protection of the guanidinium group of Boc-arginine. Abbreviations: Boc, tert-butoxycarbonyl; DCM, dichlo-
romethane; DIPEA, N,N-diisopropylethylamine; Fmoc, 9-fluorenylmethoxycarbonyl; TMS, trimethylsilyl.







10. Transfer the reaction mixture into a 250-mL separatory funnel and wash with 50 mL
water. Wash the aqueous layer three times each with 50 mL DCM.
11. Dry the combined organic layer over anhydrous Na2SO4. Add more Na2SO4 if the
salt crystals clump together upon swirling.
When the solution is dry, the nonhydrated crystals will float in solution upon swirling.
12. Gravity filter the resulting solution through filter paper into a 500-mL round-bottom
flask. Rinse the Na2SO4 crystals with 10 to 20 mL DCM.
13. Remove the solvent under reduced pressure (i.e., in a rotary evaporator with water
aspirator) to yield an orange oil.
Monitor reaction by TLC
14. Dissolve an aliquot of oil in a minimal amount of DCM, spot the solution onto a
precut 2 × 5–cm TLC plate, and develop using 93:5:2 (v/v/v) DCM/MeOH/acetic
acid (APPENDIX 3D).
CAUTION: Wear protective eyewear.
15. Visualize the spots under a 254-nm UV light source.
TLC analysis should indicate a main product with Rf = 0.54 that corresponds to the desired
amino acid derivative. Minor amounts of fast-moving products are usually present in the
mixture.
Isolate and characterize product
16. Dissolve the orange oil in 1.5 to 2 mL DCM and pour the solution onto 30 mL hexanes.
A yellowish precipitate is obtained. This procedure partially eliminates the less polar
contaminants.
17. Filter the precipitate under vacuum.
18. Prepare a 5 × 25–cm glass chromatography column with solvent reservoir bulb by
adding a slurry of 50 g of 230- to 400-mesh silica gel in 1:1 (v/v) hexanes/DCM.
Precondition with the same solvent.
19. Dissolve the crude material in a minimum amount of 1:1 hexanes/DCM and load onto
the column. Perform chromatography using a small amount of air pressure (APPENDIX




99:1, 98:2, 97:3, 96:4, and 95:5 (v/v) DCM/MeOH.
20. Combine the product-containing fractions into a 500-mL round-bottom flask and
concentrate to a white solid (60% yield) on a rotary evaporator.
21. Determine the melting temperature. Characterize by TLC, 1H and 13C NMR, IR, and
mass spectrometry.
Boc-Arg(Fmoc)2-OH: Rf 0.54 (93:5:2 DCM/MeOH/AcOH); m.p. 106°-109°C; 1H NMR
(300 MHz, CDCl3): δ 7.81-7.26 (m, 16H), 5.14 (m, 1H), 4.75 (m, 2H), 4.30 (m, 5H), 3.52
(m, 2H), 1.43 (s, 9H), 1.26 (m, 4H) ppm; 13C NMR (75 MHz, CDCl3): δ 161, 159, 157,
128, 120, 78, 68, 47, 44, 29, 28, 25 ppm; IR (film): 3800, 1720, 1620, 1515, 1460, 1260,
1110 cm–1; FAB-MS (positive mode, magic bullet, 3:1 dithiothreitol/dithioerythritol): m/z
719.4 [(Boc-Arg(Fmoc)2-OH)+H]
+, calcd. mass for C41H42N4O8: 718.8.


















Sodium sulfate (Na2SO4), anhydrous
50-mL and 250-mL round-bottom flasks
100-mL separatory funnel
Gravity filtration device and filter paper
Rotary evaporator equipped with water aspirator
Additional reagents and equipment for TLC (APPENDIX 3D), 1H NMR, and mass
spectrometry
Introduce Boc protecting group
1. Place 0.5 g (2.4 mmol) S-(tert-butylthio)-L-cysteine in a 50-mL round-bottom flask.
2. Suspend in 15 mL of 2:1 (v/v) dioxane/water and adjust the pH to 9 by addition of 1
M NaOH.
3. Add 0.60 g (2.74 mmol) di-tert-butyldicarbonate and keep the reaction overnight at
room temperature with magnetic stirring.
To avoid decomposition of di-tert-butyldicarbonate, store at –20°C.
Work up reaction
4. Transfer the reaction mixture to a 100-mL separatory funnel and wash twice with 50
mL hexanes.
5. Cool the aqueous phase in an ice bath and add 1 M HCl dropwise with manual stirring
until the pH is 2 to 3.
6. Transfer the acidified aqueous phase to the 100-mL separatory funnel and extract
three times with 50 mL EtOAc.
7. Wash the combined organic phases two times with 25 mL water.
8. Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals
clump together upon swirling.









Figure 4.22.6 Protection of the α-amine of H-Cys(S-tBu)-OH. Boc, tert-butoxycarbonyl.






9. Gravity filter the resulting solution through filter paper into a 250-mL round-bottom
flask. Rinse the Na2SO4 crystals with 10 to 20 mL EtOAc.
10. Remove the solvent under reduced pressure (i.e., in a rotary evaporator with a water
aspirator) to yield a white solid (80% yield). Use without further purification.
11. Determine the melting temperature. Characterize by TLC, 1H NMR, and mass
spectrometry.
Boc-Cys(S-tBu)-OH: Rf 0.47 (95:5 DCM/MeOH); m.p. 119°-120°C; 1H NMR (300 MHz,
CDCl3): δ 5.40 (d, 1H, J = 7.8 Hz), 4.61 (m, 1H), 3.20 (m, 2H), 1.47 (s, 9H), 1.34 (s, 9H)
ppm; FAB-MS (positive mode, 4-nitrobenzyl alcohol): m/z 309.4 [(Boc-Cys(S-tBu)-




Boc protection and tritylation of homoserine are shown in Figure 4.22.7.
Materials
L-Homoserine (Novabiochem)







Dichloromethane (DCM), neutralized (see recipe)
Methanol (MeOH)
Triethylamine
Acetonitrile, anhydrous (see recipe)
250-mL oven-dried round-bottom flask with rubber septum
Oven-dried glass syringes and needles
Rotary evaporator equipped with a water aspirator
500-mL round-bottom flask
Additional reagents and equipment for column chromatography (see Support
Protocol 2 and APPENDIX 3E), TLC (APPENDIX 3D), 1H and 13C NMR, and mass
spectrometry
Introduce Boc protecting group
1. Place 0.5 g (4.20 mmol) of L-homoserine in a 250-mL oven-dried round-bottom flask.
2. Dry by co-evaporating twice with 25 mL anhydrous pyridine.
3. Cap the flask with a rubber septum and purge the flask with dry Ar.
4. Add 10 mL anhydrous pyridine and 3.50 mL (25.2 mmol) chlorotrimethylsilane with
oven-dried glass syringes and needles.
5. Let the reaction stand 2 hr under an Ar atmosphere at room temperature.
6. Add 1.1 g (5 mmol) di-tert-butyldicarbonate and 0.7 mL (5 mmol) triethylamine, and
stir continuously 20 hr at room temperature under an Ar atmosphere.
7. Slowly add 10 mL cold water and 7 mL concentrated ammonium hydroxide (32%
v/v), and stir 30 min at room temperature.
The final ammonium hydroxide concentration achieved (∼ 2 M) will ensure complete
removal of silyl groups.






8. Evaporate to dryness under reduced pressure (i.e., in a rotary evaporator) to yield an
oil.
9. Dry the remaining oil by co-evaporating twice with 25 mL anhydrous pyridine.
10. Dissolve in 10 mL anhydrous pyridine and add 1.75 g (5.2 mmol) DMTr⋅Cl.
11. Stir 24 hr at room temperature under an Ar atmosphere.
12. Evaporate to dryness under reduced pressure.
Isolate and characterize the product
13. Perform silica gel column chromatography (see Support Protocol 2, steps 18 to 19,
and APPENDIX 3E), eluting with neutralized DCM and increasing amounts of MeOH
(0% to 10%) in the presence of 2% triethylamine.
14. Combine the product-containing fractions in a 500-mL round-bottom flask and
concentrate to an oil in a rotary evaporator.
15. Remove residual triethylamine by co-evaporating the oil with anhydrous acetonitrile
to provide the pure product as a white solid (35% yield).
16. Determine the melting temperature. Characterize by TLC, 1H and 13C NMR, and mass
spectrometry.
Boc-Hse(DMTr)-O–HNEt3
+: Rf 0.62 (9:1 DCM/MeOH); m.p. 67°-68°C; [α]D = 9.93 (c
0.62, MeOH); 1H NMR (300 MHz, CDCl3): δ 7.44-7.15 (m, 9H), 6.82-6.78 (m, 4H), 5.55
(d, 1H, J = 7.2 Hz), 4.22 (m, 1H), 3.77 (s, 6H), 3.30-3.10 (m, 2H), 2.98 (q, 6H, J = 7.3 Hz),
2.17 (m, 1H), 1.99 (m, 1H), 1.39 (s, 9H), 1.19 (t, 9H, J = 7.3 Hz) ppm; 13C NMR (75 MHz,
CDCl3): δ 176.1, 158.3, 155.2, 145.1, 135.4, 130.0-126.5, 113.0, 86.1, 60.8, 55.1, 52.8,
45.0, 32.7, 28.3, 8.4 ppm; FAB-MS (positive mode, Xe, magic bullet, 3:1 dithiothrei-
tol/dithioerythritol): m/z 623.1 [(Boc-Hse(DMTr)-O–HNEt3
+)+H]+ and 522.1 [(Boc-
Hse(DMTr)-OH)+H]+, calcd. mass for C38H50N2O7 (Boc-Hse(DMTr)-O
–HNEt3
+): 622.8,

























Figure 4.22.7 Synthesis of the homoserine derivative. Abbreviations: Boc, tert-butoxycarbonyl; DMTr, 4,4′-dimethoxytrityl;
Pyr, pyridine; TEA, triethylamine; TMS, trimethylsilyl.
















5% (w/v) aqueous sodium hydrogencarbonate (NaHCO3) solution




















































Figure 4.22.8 Protection of the threonine hydroxyl group and preparation of its solid dicyclohexylammonium salt. Abbre-
viations: Boc, tert-butoxycarbonyl; DCHA, N,N-dicyclohexylamine; DMAP, 4-(N,N-dimethylamino)pyridine; TEA, triethy-
lamine.






100-, 250-, and 500-mL round-bottom flasks
Reflux condenser
Gravity filtration device and filter paper
250- and 500-mL separatory funnels
Rotary evaporator with a water aspirator
25-mL oven-dried round-bottom flask with rubber septum
Additional reagents and equipment for column chromatography (see Support
Protocol 2 and APPENDIX 3E), TLC (APPENDIX 3E), 1H and 13C NMR, IR, and mass
spectrometry
Prepare Boc-Thr-ONbn
1. Place 2.5 g (12.5 mmol) of N-(tert-butoxycarbonyl)-L-threonine in a 100-mL round-
bottom flask. Add 20 mL EtOAc.
2. Add 3.4 g (15.7 mmol) 4-nitrobenzyl bromide and 1.6 g (15.7 mmol) triethylamine
and reflux 6 hr.
3. Cool the resulting solution and gravity filter through filter paper.
4. Transfer the filtrate to a 500-mL separatory funnel and wash once with 50 mL water,
once with 50 mL of 1 M HCl, and three times with 50 mL of 5% aqueous NaHCO3
solution.
5. Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals
clump together upon swirling.
6. Gravity filter the resulting solution through filter paper into a 250-mL round-bottom
flask. Rinse the Na2SO4 crystals with 10 to 20 mL EtOAc.
7. Remove the solvent under reduced pressure (i.e., in a rotary evaporator with a water
aspirator).
8. Perform silica gel column chromatography (see Support Protocol 2, steps 18 and 19,
and APPENDIX 3E), eluting with DCM and increasing amounts of MeOH (0% to 5%).
9. Combine product-containing fractions into a 500-mL round-bottom flask and con-
centrate to a white solid (70% yield) on a rotary evaporator.
10. Determine the melting temperature. Characterize by TLC (APPENDIX 3D), 1H and 13C
NMR, IR, and mass spectrometry.
Boc-Thr-ONbn: Rf 0.60 (95:5 CHCl3/MeOH); m.p. 95°-98°C; [α]D = –9.8 (c 0.62,
MeOH); 1H NMR (300 MHz, CDCl3): δ 8.2 (d, 2H, J = 8.8 Hz), 7.5 (d, 2H, J = 8.8 Hz),
5.4 (m, 1H), 5.3 (d, 1H, J = 3.2 Hz), 4.4 (m, 2H), 1.5 (s, 9H), 1.3 (d, 3H, J = 6.6 Hz) ppm;
13C NMR (75 MHz, CDCl3): δ 171, 156, 152, 143, 128, 124, 80, 68, 66, 59, 28, 20 ppm;
IR (KBr): 3450, 1760, 1670, 1520, 1350 cm–1; FAB-MS (positive mode, Xe, magic bullet):
m/z 355.1 [(Boc-Thr-ONbn)+H]+, 377.0 [(Boc-Thr-ONbn)+Na]+, calcd. mass for
C16H22N2O7: 354.36.
Prepare Boc-Thr(Ac)-ONbn
11. Place 3.2 g (9 mmol) of Boc-Thr-ONbn in a 100-mL round-bottom flask. Dissolve
in 20 mL EtOAc.
12. Add 4.3 mL (45 mmol) acetic anhydride and 0.55 g (4.5 mmol) DMAP and stir for
2 hr at room temperature.
13. Add 10 mL MeOH and stir 10 min.
14. Concentrate to an oil in a rotary evaporator.
15. Perform silica gel column chromatography as in step 8.
16. Combine the product-containing fractions in a 500-mL round-bottom flask and
concentrate to an oil (95% yield) in a rotary evaporator.






17. Characterize by TLC, 1H and 13C NMR, IR, and mass spectrometry.
Boc-Thr(Ac)-ONbn: Rf 0.84 (95:5 CHCl3/MeOH); [α]D = −7.2 (c 0.23, MeOH); 1H NMR
(300 MHz, CDCl3): δ 8.2 (d, 2H, J = 8.8 Hz), 7.5 (d, 2H, J = 8.8 Hz), 5.4 (m, 1H), 5.2
(d,1H, J = 3.6 Hz), 4.5 (dd, 1H, J = 2.2, 9.4 Hz), 2.1 (s, 3H), 1.5 (s, 9H), 1.3 (d, 3H, J =
6.2 Hz), ppm; 13C NMR (75 MHz, CDCl3): δ 177, 170, 156, 148, 142, 129, 124, 81, 70, 66,
57, 28, 21 ppm; IR (film): 1750, 1710, 1610, 1530, 1350 cm−1; FAB-MS (positive mode,
Xe, nitrobenzyl alcohol): m/z 397.0 [(Boc-Thr(Ac)-ONbn)+H]+, calcd. mass for
C18H24N2O8: 396.40.
Prepare Boc-Thr(Ac)-OH (oil)
18. Place 0.95 g (2.4 mmol) Boc-Thr(Ac)-ONbn into a 25-mL oven-dried round-bottom
flask. Cap the flask with a rubber septum and purge with dry Ar.
19. Dissolve in 10 mL of 1:1 (v/v) EtOAc/MeOH.
20. Add 0.18 mg of 5% palladium on activated carbon. Bubble hydrogen gas into the
reaction mixture for 3 hr.
CAUTION: Hydrogen is an extremely flammable gas. Keep the container in a well-venti-
lated place away from sources of ignition. Take precautionary measures against static
discharges. Always manipulate in a well-ventilated fume hood and wear appropriate
protective laboratory equipment.
21. Eliminate the catalyst by gravity filtration through filter paper. Rinse with 10 to 20
mL MeOH.
22. Concentrate the filtrate to dryness in a rotary evaporator.
23. Dissolve the resulting oil in 100 mL EtOAc and transfer to a 250-mL separatory
funnel.
24. Wash the organic layer six times with 50 mL of 1 M HCl and then three times with
50 mL water.
25. Dry the organic layer over anhydrous Na2SO4. Add more Na2SO4 if the salt crystals
clump together upon swirling.
26. Gravity filter the resulting solution through filter paper into a 250-mL round-bottom
flask. Rinse the Na2SO4 crystals with 10 to 20 mL EtOAc.
27. Remove the solvent under reduced pressure (i.e., in a rotary evaporator).
28. Perform silica gel column chromatography as in step 8.
29. Combine the product-containing fractions into a 500-mL round-bottom flask and
concentrate to an oil (55% yield) in a rotary evaporator.
30. Characterize by TLC, 1H and 13C NMR, and IR.
Boc-Thr(Ac)-OH: Rf 0.71 (95:5 CHCl3/MeOH); 
1H NMR (300 MHz, CDCl3): δ 5.75 (m,
1H), 4.39 (m, 1H), 4.26 (d, 1H, J = 8.6 Hz), 4.15 (m, 1H), 1.45 (s, 9H), 1.25 (d, 3H, J =
5.6 Hz) ppm; 13C NMR (75 MHz, CDCl3): 174, 170, 156, 81, 71, 57, 28, 21, 17 ppm; IR
(film): 3400, 1750, 1710, 1520 cm–1.
Prepare Boc-Thr(Ac)-O–DCHA+ (solid)
31. Dissolve Boc-Thr(Ac)-OH in 1:1 (v/v) hexanes/diethyl ether and add an equimolar
amount of dicyclohexylamine. Stir overnight at 0°C.
32. Filter and then wash with prechilled 1:1 (v/v) hexanes/diethyl ether to obtain a white
solid (93% yield).






33. Characterize by TLC, 13C NMR, and mass spectrometry.
Boc-Thr(Ac)-O–DCHA+: Rf 0.47 (85:10:5 CHCl3/MeOH/AcOH); m.p. 172°-173°C; 13C
NMR (75 MHz, CDCl3): δ 174, 170, 156, 78, 73, 59, 53, 29, 28, 25, 24, 21, 17 ppm; FAB-MS
(positive mode, Xe, magic bullet, 3:1 dithiothreitol/dithioerythritol): m/z 443.0 [(Boc-




ELONGATION OF THE OLIGONUCLEOTIDE CHAIN AND CLEAVAGE
AND DEPROTECTION OF THE NUCLEOPEPTIDE
In this protocol, the peptide-bound support is added to an oligonucleotide synthesis
column and the nucleotide is extended from the appropriate amino acid hydroxyl function
(homoserine in Fig. 4.22.2B). In general, oligonucleotide synthesis follows standard
automated DNA methods (see APPENDIX 3C); however, some minor modifications have to
be introduced in the oligonucleotide synthesis cycle, since a polystyrene support is used
instead of controlled-pore glass (CPG). The main washes are made with neutralized DCM
rather than acetonitrile, and THF washes are used after certain steps. A 2% N,N-diiso-
propylethylamine solution is used to wash the support after detritylation. Washes with
anhydrous acetonitrile are employed before phosphoramidite couplings. The synthesis
cycle is outlined in Table 4.22.3. Oligonucleotide synthesis is monitored by the trityl
assay, and the yield of the first incorporation is also determined.
Complete deprotection of the nucleopeptide can be carried out using ammonium hydrox-
ide alone or using tetra-n-butylammonium fluoride (TBAF) followed by ammonium
hydroxide. Ammonia treatment may give (especially with glycine at the C terminus) a
mixture of the C-terminal carboxylic acid and carboxamide nucleopeptides. The TBAF
procedure gives exclusively the C-terminal carboxylic acid nucleopeptide irrespective of
the bifunctional spacer used. The TBAF treatment is recommended if nucleopeptides are
sufficiently stable, but may not be compatible with nucleopeptides in which serine or
threonine are the linking residues (see Strategic Planning). In some cases, presence of
tetra-n-butylammonium counterions renders the reversed-phase HPLC analysis (see
Basic Protocol 3) difficult. In those cases, it is recommended to obtain the sodium salt of
the nucleopeptide as described below. PAGE analysis (see Basic Protocol 4) is also more
reliable with desalted products. For additional requirements for deprotection, analysis,
and purification, see Support Protocol 7.
Materials
Peptide-derivatized support (see Basic Protocol 1)
DNA phosphoramidites (Glen Research): 5′-O-(4,4′-dimethoxytrityl)-N-protected-
2′-deoxyribonucleoside-3′-O-(2-cyanoethyl-N,N-diisopropyl)-phosphoramidites, 







Argon (Ar) and nitrogen (N2, optional) gas, dry
Anhydrous acetonitrile (see recipe) in a septum-sealed distillation collection bulb
Activator solution (see recipe)
Cap A and B capping reagents (Glen Research)
Oxidizer solution (see recipe)
Peroxide-free THF (see recipe)






Table 4.22.3 Automated 5-µmol Synthesis Cycle for the Oligonucleotide Chain
Elongation on an ABI 380B DNA Synthesizer
Synthesis step Function Time (sec)
Detritylation
1 DCM to waste 5
2 DCM to column 20
3 Ar reverse flush 10
4 Ar block flush 5
5 Waste port 1
6 Advance fraction collector 1
7 3% TCA to waste 5
8 3% TCA to column 60
9 Ar column flush 10
10 3% TCA to column 60
11 Ar column flush 10
12 DCM to waste 3
13 DCM to column 180
14 Ar column flush 10
15 Ar block flush 5
16 Waste to bottle 1
17 2% DIPEA to waste 3
18 2% DIPEA to column 30
19 Ar reverse flush 10
20 DCM to waste 3
21 DCM to column 20
22 Ar reverse flush 10
Column washing
23 ACN to waste 5
24 ACN to column 45
25 Ar reverse flush 30
26 Ar block flush 5
27 ACN to waste 5
28 ACN to column 45
29 Ar reverse flush 45
30 Ar block flush 5
Phosphoramidite coupling
30 Phosphoramidite preparation 3
31 Activator to column 3
32 Phosphoramidite + activator to column 25
33 Activator to column 3
34 THF to waste 5
35 Wait 300
36 THF to column 30
37 Ar reverse flush 10
38 Ar block flush 5
continued






Detritylation solution: 3% (w/v) trichloroacetic acid (TCA, 99%, Glen Research)
in neutralized DCM
2% (v/v) N,N-diisopropylethylamine (DIPEA) in neutralized DCM
Neutralized DCM (see recipe)
0.1 M p-toluenesulfonic acid monohydrate in acetonitrile
70% (v/v) perchloric acid
Absolute ethanol (EtOH)
Peroxide-free dioxane (see recipe)
32% ammonium hydroxide (store at 4°C)
1 M dithiothreitol (DTT) in peroxide-free dioxane
Tetra-n-butylammonium fluoride (TBAF, Aldrich)
Anhydrous tetrahydrafuran (see recipe) in a septum-sealed distillation collection
bulb
Methanol (MeOH), HPLC grade
Glacial acetic acid
200- to 400-mesh Dowex 50WX4-400 ion-exchange resin (4.8 meq Na+/g; Fluka
Chemic)
1 M NaOH
Synthesis column for 5-µmol-scale synthesis: old empty OPC cartridge (ABI)
with a body and two caps (13-mm aluminum seals; Chromatographic
Specialties)
Column capping
39 Capping preparation 10
40 Cap A + cap B to column 30
41 Wait 120
42 DCM to waste 5
43 DCM to column 45
44 Ar reverse flush 10
45 Ar block flush 5
Oxidation and column washing
46 Oxidizer to waste 7
47 Oxidizer to column 30
48 DCM to waste 5
49 Wait 60
50 THF to waste 5
51 THF to column 60
52 Ar reverse flush 10
53 DCM to waste 5
54 DCM to column 30
55 Ar reverse flush 10
56 Ar block flush 5
57 Repeat steps 54 and 55 three times
58 Ar block flush 5
Table 4.22.3 Automated 5-µmol Synthesis Cycle for the Oligonucleotide Chain
Elongation on an ABI 380B DNA Synthesizer, continued
Synthesis step Function Time (sec)






Empty DNA synthesizer bottles, oven dried, with rubber septa
Vacuum desiccator containing P2O5
Glass syringes and needles, oven dried
ABI 380B automated DNA synthesizer
External fraction collector and 15-mL test tubes
Double-beam UV spectrophotometer, calibrated, and quartz cuvettes
20-mL screw-cap pressure tubes, O-ring seal preferred
55°C oven




Rotary evaporator with a water aspirator
Lyophilizer
Vacuum filtration system
Additional reagents and equipment for automated oligonucleotide synthesis
(APPENDIX 3C) and amino acid analysis (see Basic Protocol 1)
CAUTION: All solutions and reagents required for the DNA synthesizer should be
manipulated and prepared in a well-ventilated fume hood.
NOTE: Oxidizer solution, DIPEA solution, neutralized DCM, and peroxide-free THF
should be filtered (Pro-XR nylon filters, 0.25 µm, 25 mm) before they are added to the
synthesizer bottles.
Prepare column
1. Transfer an accurately weighed amount of peptide-derivatized support for a 5-µmol
synthesis (i.e., 100 mg peptide-support with a loading of 0.20 µmol/mg) to an
assembled oligonucleotide synthesis column.
The peptide-resin contains the hydroxyl function where the first nucleotide will be anchored
and the oligonucleotide chain subsequently elongated.
Standard 1-mol scale columns may fit enough a resin for a 1 to 2-mol-scale synthesis
on polystyrene.
Perform oligonucleotide synthesis
2. Weigh the appropriate amount of DNA phosphoramidites in oven-dried synthesizer
bottles, cap with rubber septa, insert a disposable needle, and dry them in a P2O5-con-
taining desiccator under vacuum (6 hr minimum).
3. Open the desiccator under an Ar atmosphere. Using oven-dried glass syringes and
needles, dissolve the compounds in sufficient anhydrous acetonitrile (from a septum-
sealed distillation collection bulb) to yield a 0.2 M concentration.
Care must be taken to avoid the presence of moisture throughout the entire process.
4. Place the synthesizer reagents in the following ports of an ABI 380B synthesizer:
Activator: port 9
Cap A and B: ports 11 and 12
Oxidizer: port 15
Peroxide-free THF: port 16
Detritylation solution: port 14
2% DIPEA in neutralized DCM: port 17
Neutralized DCM: port 18
Anhydrous acetonitrile: port 13
DNA phosphoramidite solutions (step 3): ports 1 to 4.






5. Enter the sequence to be synthesized. Introduce an additional nucleotide at the 3′ end
that will correspond to the peptide-resin containing the hydroxyl function where the
oligonucleotide will be anchored.
For example, to synthesize the tryptophan-containing nucleopeptide shown in Figure
4.22.2B, enter the sequence 5′-GCTACGT-3′, where the 3′-T corresponds to the peptide-
linked resin.
6. Perform synthesis in the DMTr-off mode using a synthesis cycle modified as outlined
in Table 4.22.3. Collect DMTr cation solutions in 15-mL test tubes using an external
fraction collector.
When nucleopeptides with >10 nucleobases are prepared, synthesis in DMTr-on mode is
recommended in order to facilitate the purification.
7. Upon completion of the synthesis, dry the resin by manually conducting an Ar reverse
flush operation on the synthesizer for 2 to 3 min. Alternatively, dry the support under
a stream of N2 or Ar.
Monitor DNA synthesis by DMTr assay
8. Dilute the first three and last three DMTr cation solutions to 10 mL with 0.1 M
p-toluenesulfonic acid monohydrate in acetonitrile. Mix thoroughly.
CAUTION: Handle the solution containing trichloroacetic acid in DCM and acetonitrile
with gloves, because it is corrosive as well as toxic. Always manipulate in a well-ventilated
fume hood.
The volume of DMTr solutions may change during the course of a synthesis because DCM
is a volatile solvent. Fractions may sit for several days before being assayed without
affecting the results. Samples that have gone to dryness must be thoroughly redissolved.
Addition of the p-toluenesulfonic acid ensures ionization of the DMTr group, making the
solutions more strongly colored.
9. Dilute each sample 20- to 50-fold with the same solution. Measure the absorbance
at 498 nm (A498) versus the 0.1 M p-toluenesulfonic acid monohydrate solution in
acetonitrile.
These dilutions are necessary because high absorbance measurements are not reliable.
10. Calculate the rough stepwise coupling efficiency for the synthesis as a whole, using
the following equation:
where n is the number of DMTr nucleotides in the oligonucleotide (equal to the length
of the oligonucleotide for DMTr-off synthesis).
Quantify incorporation yield of the first nucleotide
11. Evaporate the first DMTr cation solution to dryness and redissolve the remaining
residue in a known volume of 3:2 (v/v) 70% perchloric acid/EtOH.
CAUTION: Handle 3:2 (v/v) 70% perchloric acid/EtOH with gloves in a well-ventilated
fume hood. Perchloric acid is very corrosive and can be explosive when it contacts organic
materials. Perchloric-containing residues must be appropriately neutralized prior to
disposal.
12. Dilute the sample 20- to 50-fold with the same solution in order to obtain an A498
<1. Measure the A498 of the sample versus the 3:2 (v/v) 70% perchloric acid/EtOH
solution.
avg. absorbance last three fractions
(stepwise efficiency)
avg. absorbance first three fractions
n =
Equation 4.22.2






13. Calculate loading as:
where DF is the dilution factor, ε is the molar extinction coefficient of the DMTr
cation at 498 nm (71,700 L/mol⋅cm), l is the absorbance path of the cuvette (in cm),
and m is the amount of peptide-support introduced in the column (in mg).
14. Determine the incorporation yield of the first nucleotide onto the peptide-support as
the ratio between the obtained loading value and the peptide-support loading deter-
mined by amino acid analysis.
Perform complete deprotection of nucleopeptide
With ammonium hydroxide treatment
15a. Open the column and transfer the nucleopeptide-support to a 20-mL screw-cap
pressure tube, preferably with an O-ring seal.
16a. Add 5 mL peroxide-free dioxane and 5 mL of 32% ammonium hydroxide. Screw
the cap on tightly, and incubate 15 hr at 55°C in an oven or 6 to 8 hr at room
temperature (see Strategic Planning for more details). When the nucleopeptide
contains Cys(S-tBu), use 5 mL of 1 M DTT in dioxane and 5 mL of 32% ammonium
hydroxide and treat for 6 to 8 hr at room temperature (see Support Protocol 7).
CAUTION: The 32% ammonium hydroxide solution must be kept at 4°C with the cap tightly
sealed. Concentrated ammonium hydroxide is extremely caustic. Breathing the vapors is
harmful. Always wear glasses and gloves when using this compound and work in a
well-ventilated fume hood, as it is possible to be quickly overcome by ammonia fumes and
be blinded.
17a. Cool the mixture to room temperature. Filter through a disposable polypropylene
syringe with a polyethylene filter or cotton, and collect in a 50-mL round-bottom
flask.
18a. Wash the pressure tube several times with MeOH and pass the washes through the
syringe. Concentrate the resulting filtrate under reduced pressure to a volume of ∼2
mL.
To prevent inadvertent detritylation of dimethoxytritylated nucleopeptides, avoid heat and
acid during the evaporation step. Elimination of dioxane and ammonium hydroxide should
be done at room temperature to preserve the 5′-DMTr on the oligonucleotide chain.
Addition of triethylamine is recommended to ensure no loss of the DMTr group.
With TBAF and ammonium hydroxide treatment
15b. Open the column and transfer the nucleopeptide-support into a polypropylene
disposable syringe with a polyethylene filter closed with a stopcock.
16b. Add 5 mL of 0.05 M TBAF in anhydrous THF and let stand 30 min, stirring
occasionally.
17b. Collect the filtrate in a 50-mL round-bottom flask. Wash three times with 2 mL
MeOH followed by 5 mL THF and add to the filtrate. Add a few drops of glacial
acetic acid and evaporate to dryness using a rotary evaporator.
498  DF 1000loading = 












18b. Redissolve the residue in 10 mL of 1:1 (v/v) peroxide-free dioxane/32% ammonium
hydroxide and place in a 55oC oven for 15 hr, or at room temperature for 6 to 8 hr,
depending on the stability expected for the target nucleopeptides. Concentrate the
resulting filtrate under reduced pressure to a volume of ~2 mL.
Obtain sodium salt of nucleopeptide (optional; for TBAF only)
19. Add 200- to 400-mesh Dowex 50WX4-400 ion-exchange resin to a polypropylene
syringe fitted with a polyethylene disc.
20. Wash with 200 mL water.
21. Wash with 200 mL of 1 M NaOH, added dropwise.
22. Wash with water until the solution has the pH of deionized water.
23. Dissolve deprotected nucleopeptide residue (step 18b) in a minimum amount of water
(1 to 2 mL) and load onto the equilibrated Dowex resin. Elute with water until no
UV-absorbing filtrate is obtained (check by measuring the absorbance at 260 nm
versus water). Collect 1 to 2 mL fractions in disposable tubes.
24. Combine the product-containing fractions and lyophilize.
Calculate cleavage yield
25. Wash the resin (resulting from ammonia or TBAF treatment; step 17a or 17b) with
MeOH and dry directly on a vacuum filtration system.
26. Proceed with amino acid analysis as described (see Basic Protocol 1, steps 9 to 13).
27. Calculate the cleavage yield as the ratio between any amino acid in the nucleopeptide
still attached to the solid support and the internal reference amino acid.
Choose residues that are not destroyed or modified during the hydrolysis process, such as
amino acids with aliphatic side chains, phenylalanine, or aspartic and glutamic acids.
BASIC
PROTOCOL 3
ANALYSIS, PURIFICATION, AND CHARACTERIZATION OF
NUCLEOPEPTIDES
Crude nucleopeptides are first analyzed and then purified by liquid chromatography
techniques. Analysis is routinely carried out using reversed-phase HPLC (RP-HPLC),
although analytical PAGE (see Basic Protocol 4) can provide additional information, or
may be required if the sample is highly impure. Purification is also generally performed
by RP-HPLC. Medium-pressure systems (MPLC) may be the best option for relatively
homogeneous crude nucleopeptides, since relatively large amounts of product (30 to 1000
OD units) can be purified in a single run. When this technique is inefficient, or if
complicated crude nucleopeptides are obtained, the higher resolving power of high-pres-
sure systems is required. Either analytical or semipreparative HPLC columns can be used,
depending on the amount of pure product to be isolated. Preparative gel electrophoresis
(see Basic Protocol 4) provides very good resolution and may allow pure nucleopeptides
to be obtained when RP-HPLC fails. Its main disadvantage is low recovery of product
from the gel.
After purification, the overall synthesis yield is determined and the nucleopeptide is
quantified by spectrophotometry at 260 nm. The nucleopeptide is then analyzed by
MALDI-TOF or ESI mass spectrometry. Oligonucleotide analysis, purification, and
characterization procedures are described in UNITS 10.1-10.7. Base composition is deter-
mined by digestion using a combination of alkaline phosphatase (AP) and either snake
venom phosphodiesterase (SVPD) or calf spleen phosphodiesterase (SpPD). The assess-
ment of base composition is more often carried out using SVPD than SpPD. Degradation
with SVPD and AP can be performed in a single reaction mixture, because both enzymes
work at the same slightly basic pH. Degradation with SpPD and AP requires two separate






treatments under different conditions. The same information is generally obtained using
either protocol, and consistent results from both reinforce that the nucleoside composition
is as expected.
Finally, the product is analyzed by amino acid analysis after acid hydrolysis or enzymatic
digestion of the peptide moiety. Enzymatic digestion is carried out in a sequential mode
using three enzymes: papaine, microsomal leucin-aminopeptidase, and prolidase. (1)
Papaine is a nonspecific enzyme that cleaves at -X-↑-Y-, where Y is not specific and X
can be any residue, but is preferably arginine, lysine, or residues consecutive to phenyl-
alanine. (2) Microsomal leucin-aminopeptidase is an exopeptidase that hydrolyzes pep-
tide bonds adjacent to a free α-amine group (H2N-X-↑-Y-, where X is not proline and Y
is not specific). It does not hydrolyze γ-amino groups. (3) Prolidase is a dipeptidase that
hydrolyzes dipeptides with a proline or hydroxyproline residue at the C terminus (H2N-
X-↑-Y-, where X is not proline, but Y is proline or hydroxyproline). When coupled with
amino acid analysis, this protocol allows the content of asparagine and aspartic acid to be
determined, as well as other acid-labile amino acids (e.g., methionine, tryptophan).
Materials
Crude deprotected nucleopeptide (see Basic Protocol 2 or Support Protocol 7)
0.01 M ammonium acetate, pH 7.0
HPLC mobile phase A: 0.01 M ammonium acetate, pH 7.0
HPLC mobile phase B: 1:1 (v/v) acetonitrile/water
Methanol (MeOH), HPLC grade
MPLC mobile phase A: 0.05 M ammonium acetate, pH 7.0
MPLC mobile phase B: 70% (v/v) 0.05 M ammonium acetate solution, pH 7.0, in
1:1 (v/v) acetonitrile/water




0.1% (v/v) triethylamine in water
Isopropanol (optional)
0.1 M Tris⋅Cl, pH 8.0 (APPENDIX 2A)
0.1 M MgCl2
1.5 U/500 µL snake venom phosphodiesterase (SVDP; Boehringer-Mannheim; EC
3.1.4.1)
0.0337 U/µL bacterial alkaline phosphatase (AP; Sigma; EC 3.1.16.1)
0.2 M ammonium acetate, pH 5.4 and 8.3
0.23 U/µL calf spleen phosphodiesterase (SpPD; Sigma; EC 3.1.3.1)
Concentrated HCl
0.1 M ammonium acetate, pH 5.3
1:32 (v/v) 2-mercaptoethanol/water
20 mg/mL (286 U/mL) papaine (from Papaya latex; Sigma; EC 3.4.22.2)
Glacial acetic acid
3 mg/mL (72 U/mL) microsomal leucin aminopeptidase (mLAP type VI-S from
kidney pork microsomes; Sigma; EC 3.4.11.2)
0.025 M MnCl2 buffer solution, pH 8.3
5 mg/mL (875 U/mL) prolidase (from pork kidney; Sigma; EC 3.4.13.9)
High-performance liquid chromatograph (HPLC) with:
 Injector (autosampler preferred), sample loop, and syringe (for manual loading)
 0.1 to 5 mL/min pumping system (binary)
 UV/Vis detector, variable wavelength between 190 and 600 nm (preferred) or 
 dual-wavelength detection






 Data integrating system
 Gradient system: displays and stores for redisplay and reformatting (preferred)
 or programmable
 Analytical column: reversed-phase C18 column (i.e., Kromasil, 10 µm, 4.0 × 
250 mm)
 Semipreparative column: reversed-phase C18 column (i.e., Kromasil, 10 µm, 
10.0 × 250 mm)
 Automatic fraction collector (optional)
Lyophilizer
Double-beam UV spectrophotometer, calibrated
Quartz cuvettes
Preparative chromatographic system (medium-pressure liquid chromatography,
MPLC):
 Piston pump
 Reversed-phase C18-filled glass column (i.e., Vydac 15 to 20-µm i.d., 300-Å 
 porosity, 22 × 2 cm)
 Automatic fraction collector
 UV/Vis detector with fixed-wavelength detection
 Teflon tubing connectors and adapters
 Gradient-forming device with two equal-diameter cylinders and a Teflon   
 stopcock between them
 Chart recorder
Pyrex tubes
37°C water bath or heating block
Benchtop centrifuge
Additional reagents and equipment for reduction of sulfoxide-protected
methionine (see Support Protocol 6; optional), deprotection of
tert-butylthio-protected cysteine (see Support Protocol 7; optional),
MALDI-TOF-MS (UNIT 10.1), ESI-MS (UNIT 10.2), and amino acid analysis (see
Basic Protocol 1)
Analyze crude nucleopeptide by analytical RP-HPLC
1. Take 0.05 to 0.10 OD units of crude deprotected nucleopeptide and dilute with 0.01
M ammonium acetate buffer, pH 7.0, to a volume of 25 to 100 µL.
Typical injection volumes for analysis are 10 to 100 L depending on the sample loop size
of the injector.
For nucleopeptides containing tert-butylthio-protected cysteine, perform deprotection (see
Support Protocol 7) prior to the analysis of the crude product.
2. Program the HPLC gradient system to start with 5% HPLC mobile phase B,
increasing the percentage of HPLC mobile phase B with time (Table 4.22.4). Ensure
that there is sufficient mobile phase to keep intakes covered throughout the run.
For 5′-dimethoxytritylated nucleopeptides 5% to 60% mobile phase B in 30 min is the
gradient recommended. For post-HPLC detritylation, see UNIT 10.5.
3. Set the UV detector wavelength at 260 nm. Using an analytical column, equilibrate
the HPLC system with the starting mobile phase composition until a flat baseline is
achieved at the desired detection wavelength.
4. Inject the sample by programming the autosampler or by loading it into the sample
loop using an appropriate syringe. Elute the sample by starting the gradient. Record
the chromatogram.






Typically, nucleopeptides will elute at ∼12 to 18 min under the recommended conditions
(Table 4.22.4). For 5′-dimethoxytritylated nucleopeptides, the elution time will be longer
(∼18 to 25 min).
In some cases, when the nucleopeptide is small (e.g., <8 nucleobases) and has been cleaved
with ammonium hydroxide, it is possible to differentiate the nucleopeptides with C-terminal
carboxylic acid and carboxamide groups.
When the nucleopeptide contains sulfoxide-protected methionine or proline, it is possible
to obtain two or more peaks (depending on the number of these residues) due to sulfoxide
diastereomers or proline conformations (cis or trans).
5. For nucleopeptides containing sulfoxide-protected methionine, proceed with reduc-
tion (see Support Protocol 6) prior to purification.
Purify crude nucleopeptide by analytical or semipreparative RP-HPLC
6a. For small amounts of nucleopeptide (1 to 10 OD units): Perform HPLC as in steps 1
to 4. Load the analytical column with ∼1 to 2 OD units at every injection and elute
at a flow rate of 1 mL/min. Collect the desired fractions either with an automated
fraction collector or by observing the chromatogram in real time and manually
collecting the eluate.
6b. For larger amounts of nucleopeptide (>10 OD units): Use a semipreparative column
under the described conditions. Elute at a flow rate of 3 mL/min.
7. Lyophilize the collected solution and quantify the amount of product obtained (steps
8 to 11).
Quantify nucleopeptide
8. Dissolve the lyophilized nucleopeptide in 5 mL water. Take 20 µL and dilute to a
volume of 1 mL with water.
An adequate dilution factor has to be chosen to keep absorbance <1. Modify the dilution
depending on the synthesis scale and expected yield.
9. Measure the absorbance of the diluted sample in a quartz cuvette at 260 nm (A260) on
a calibrated, double-beam, UV spectrophotometer using water as a reference.
If using a single-beam spectrophotometer, a blank should be run with a sample containing
water (blank).
Table 4.22.4 Gradient and Mobile Phase for RP-HPLC of
Crude Nucleopeptidea







aGradient conditions are based on a flow of 1 mL/min using an analytical
Kromasil reversed-phase C18 column (10-µm diameter spherical silica, 4.0
× 250 mm) at ambient temperature with a 45-min injection cycle. Mobile
phase A: 0.01 M ammonium acetate, pH 7.0; mobile phase B: 1:1 (v/v)
acetonitrile/water.
bPercentage is at elapsed time.






10. Determine the amount of product (in OD260 units) and the concentration of the stock
solution using the dilution factor and Beer’s Law (A260 = εlc), where ε is the molar
extinction coefficient (see below), l is the path length of the UV cell (typically 1 cm),
and c is the molar concentration of oligonucleotide. Lyophilize the nucleopeptide
solution.
In a nucleopeptide, the contribution of aromatic amino acids (tryptophan, phenylalanine,
and tyrosine) to the global oligonucleotide absorbance at 260 nm is considered negligible
in comparison with the absorption of the nucleobases.
The molar extinction coefficient of the nucleopeptide is given by ε = εi × F, where εi
represents the molar extinction coefficient of each nucleobase (see Table 4.22.5) and F is
a correction factor (0.9 when the oligonucleotide is single-stranded and 0.8 when it is
double-stranded or self-complementary).
11. Calculate the overall synthesis yield. From the ratio of product obtained (in OD units)
to the theoretical amount (calculated from the loading of the C-terminal amino acid
resin).
Average yields for nucleopeptide synthesis, cleavage, and purification are ∼10% to 30%.
Purify crude nucleopeptide by preparative MPLC
12. Prepare a preparative chromatographic system as follows:
a. Connect a piston pump to the top of a preparative reversed-phase C18-filled glass
column.
b. Connect the bottom to an automatic fraction collector through a UV/Vis detector.
c. Connect the pump to the mixing chamber of a gradient-forming device. Connect
the detector to a chart recorder using the appropriate ports.
13. Wash the column with 100 mL MeOH and 200 mL water by placing the pump
entrance line in the appropriate bottles.
14. Set the UV detector wavelength at 260 nm with the appropriate lamp and filter. Turn
on the detector and chart recorder.
15. Equilibrate the column with 200 mL MPLC mobile phase A at 3 to 4 mL/min. Stop
the pump.
16. Place 600 mL MPLC mobile phase A and 600 mL MPLC mobile phase B in the
appropriate compartments of the gradient-forming device. Place a magnetic stir bar
in the mixing chamber (initially MPLC mobile phase A) and a magnetic stirrer below.
17. Place the pump solvent line inside the mixing chamber.
18. Dissolve the crude nucleopeptide sample in MPLC mobile phase A to a volume of 5
mL.
19. Remove the supernatant solution from the column cap position. Introduce the
nucleopeptide sample solution onto the column and close.
Table 4.22.5 Molar Extinction Coefficients of Nucleobases











20. Turn on the pump (3 to 4 mL/min) and the magnetic stirrer. Open the stopcock of the
gradient-forming device to generate the gradient. Turn on the automatic fraction
collector.
Preparative chromatographic elution profiles are very similar to analytical ones. The
gradient conditions described above extrapolate the typical analytical gradient (from 5%
to 35% HPLC mobile phase B in mobile phase A). When DMTr-on nucleopeptides are
purified, MPLC mobile phase B should be changed to 40% 0.05 M ammonium acetate
solution, pH 7.0, in 1:1 (v/v) acetonitrile/water.
21. Select the tubes containing the desired product. Reanalyze those solutions by ana-
lytical HPLC (steps 1 to 4).
In general, the desired nucleopeptide (main chromatographic peak) is eluted within four
or five tubes and has a high level of purity (>95% to 99%  as assessed by analytical HPLC).
22. Pool the fractions with the same chromatographic profile and purity requirements.
Lyophilize the collected solution and quantify (steps 8 to 11).
Analyze nucleopeptide by MALDI-TOF-MS
23. Weigh 10 mg THAP matrix or 50 mg 3-HPA matrix into a 1.5-mL microcentrifuge
tube. In a separate tube, weigh 50 mg ammonium citrate.
Optimal results are obtained when the highest-purity matrices are used. Matrix and
ammonium citrate solutions should be made fresh prior to use. Storage for >3 days is not
recommended.
In general, MALDI-TOF analysis of nucleopeptides is carried out following the same
protocols as for simple oligonucleotides (UNIT 10.1). The standard matrices are used (THAP
and 3-HPA) and negative-ionization mode is recommended because of the global negative
charge of the nucleopeptides. For routine nucleopeptide analysis (up to 8 to 10 nucleo-
bases), THAP is recommended. 3-HPA should be used when THAP does not give positive
results.
24. Add 1 mL of 1:1 (v/v) acetonitrile/water to the THAP or 3-HPA matrix, and 1 mL
water to the ammonium citrate salt. Vortex for 30 sec to allow complete dissolution.
25. Prepare a 50 to 100 µM nucleopeptide solution in water.
26. To a 0.5-mL microcentrifuge tube, add 1 µL nucleopeptide sample solution, 1 µL
ammonium citrate solution, and 1 µL matrix solution. Mix by withdrawing and
expelling the solution ten times with a pipet.
27. Spot 1 µL on the MALDI-TOF sample plate and dry. To allow for homogeneous
crystallization, do not disturb the spotted sample after it starts to crystallize.
Do not load the sample plate into the mass spectrometer before the plate is dry. Good signal
can be obtained from anywhere around the edges of the crystallized spot.
28. Analyze by MALDI-TOF-MS (see UNIT 10.1).
Analyze nucleopeptide by ESI-MS
29. Prepare a 100 to 200 µM stock nucleopeptide solution in water.
The best concentration for carrying out ESI-MS analysis depends on the instrument used.
In general, nucleopeptides are analyzed by ESI-MS in the negative mode, as with MALDI-
TOF-MS. See UNIT 10.2 for more specific details.
30. Add 5 µL of 0.1% triethylamine to 100 µL nucleopeptide solution.






31. Mix 100 µL of the above solution with an equal volume of acetonitrile (preferred),
isopropanol, or MeOH.
In general, the aqueous nucleopeptide solution is mixed in a 1:1 (v/v) ratio with an organic
solvent such as acetonitrile, MeOH, or isopropanol, because the solvent is readily evapo-
rated and facilitates the transfer of the ion from the liquid to the gas phase. The solvent
also allows for the generation of a large number of ions. Another issue is that, as the pH
increases, more negative ions are produced and the signal intensity rises. Addition of an
organic base such as triethylamine to the nucleopeptide solution increases the pH and also
reduces the extent of cation adducts observed in the mass spectra.
32. Analyze by ESI-MS (UNIT 10.2).
Analyze base composition by SVPD/AP digestion
33. Evaporate 0.5 to 1.0 OD unit of nucleopeptide sample to dryness under vacuum in
an appropriate vessel (i.e., 1.5-mL microcentrifuge tube).
34. Add the following:
34 µL freshly deionized water
50 µL 0.1 M Tris⋅Cl, pH 8.0
10 µL 0.1 M MgCl2
1 µL 1.5 U/500 µL SVPD
5 µL 0.0337 U/µL bacterial AP.
35. Vortex the sample and centrifuge briefly to collect the liquid at the bottom of the tube.
Incubate 8 to 15 hr at 37°C.
36. Vortex the sample and chill with dry ice at least 10 min.
37. Centrifuge 5 min in a benchtop centrifuge at maximum speed, room temperature.
Carefully remove the supernatant with a pipet and transfer to a new labeled tube.
Discard the original tube containing the pellet.
38. Evaporate the sample to complete dryness under vacuum.
39. Dissolve the dried sample in 50 µL water and vortex at least 30 sec.
Table 4.22.6 Gradient and Mobile Phase for RP-HPLC Analysis of Nucleopeptide
Digestsa








aGradient conditions are based on a flow of 1 mL/min using a Kromasil reversed-phase C18 column (10-µm
diameter spherical silica, 4.0 × 250 mm) at ambient temperature with a 40-min injection cycle. Mobile
phase A: 0.01 M ammonium acetate, pH 7.0; mobile phase B: 1:1 (v/v) acetonitrile/water.
bPercentage is at elapsed time






40. Perform reversed-phase HPLC of the digested sample on a C18 column. Load ∼0.2
OD unit per injection and elute with an acetonitrile/ammonium acetate/water gradient
as specified in Table 4.22.6. Set the detector to 260 nm.
See UNIT 10.6 for more specific details on RP-HPLC.
41. Collect data for 30 min.
The nucleoside elution order depends on the column and HPLC system used. Approximate
elution times are 5.0 min for dC, 6.0 min for dG, 6.7 min for T, and 13.1 min for dA.
42. To calculate the base composition, use the molar extinction coefficients from Table
4.22.5 and the integrated area of each peak. First calculate the average value of the
ratio between the integrated area and the molar extinction coefficient (X):
where εi is the molar extinction coefficient of each nucleoside (Table 4.22.5) and N
the number of every particular nucleobase in the sequence. Then calculate the
composition for each nucleoside:
where ni represents the experimental calculated value for the nucleoside i.
Although SVPD is a 3′-exonuclease, it has been shown to degrade nucleopeptides where
the 3′-hydroxyl function of the oligonucleotide chain is blocked by linkage to a peptide
chain. This modification would prevent degradation during a short incubation time, but
not after long treatments as described above. Also, SVPD contains some endonuclease
contamination that favors complete degradation of the oligonucleotide chain.
In general, the nucleoside composition calculated after enzymatic digestion is very similar
to the expected composition. In some cases, the value of the 3′-nucleoside is low depending
on the amino acid that links the peptide and oligonucleotide chain. When homoserine
serine, or threonine is used, an extra peak, with higher retention time than that of simple
nucleosides, may be observed in the RP-HPLC profile that corresponds to the 3′-nucleo-
side-peptide.
Analyze base composition by SpPD/AP digestion
43. Evaporate 0.5 to 1.0 OD unit of nucleopeptide sample to dryness under vacuum in
an appropriate vessel (i.e., 1.5-mL microcentrifuge tube).
44. Add 30 µL of 0.2 M ammonium acetate buffer, pH 5.4, and 10 µL of 0.23 U/µL SpPD.
45. Vortex the sample and centrifuge briefly to collect the liquid at the bottom of the tube.
Incubate 12 to 15 hr at 37°C.
46. Lyophilize and then add the following:
34 µL freshly deionized water
50 µL 0.1 M Tris⋅Cl, pH 8.0
10 µL 0.1 M MgCl2
5 µL 0.0337 U/µL bacterial AP.
(peak area/ ) /iX N= ∑ ε
Equation 4.22.4
n (peak area/ ) /i i X= ε
Equation 4.22.5






47. Continue as in steps 35 to 42.
SpPD is a 5′-exonuclease enzyme, and degrades the oligonucleotide chain of the nu-
cleopeptide starting from the 5′-terminal hydroxyl group. SpPD also degrades the 3′-nu-
cleoside-peptide linkage, independently of the linking amino acid.
In general, nucleoside composition after enzymatic digestion is very similar to the expected
composition. In some cases, however, the deoxyadenosine value is lower than expected.
This is because of deaminase contamination, and depends on the enzyme batch employed.
In these cases, an extra peak appears in the HPLC trace, which is attributed to a modified
deoxyadenosine nucleoside.
Perform amino acid analysis of nucleopeptide under acidic conditions
48. Place 5 OD260 units of purified nucleopeptide in a Pyrex tube.
49. Add 300 µL water and 300 µL concentrated HCl.
50. Determine amino acid content as described (see Basic Protocol 1, steps 11 to 13).
When quantifying amino acids from peptide-oligonucleotide conjugates, high values of
glycine are obtained due to co-elution with oligonucleotide hydrolysis side-products.
Perform enzymatic analysis of peptides and nucleopeptides
51. Evaporate 3 to 5 nmol peptide or nucleopeptide sample to dryness under vacuum in
an appropriate vessel (i.e., a 1.5-mL microcentrifuge tube).
52. Dissolve the sample in 15 µL of 0.1 M ammonium acetate buffer, pH 5.3. Add 1 µL
of 1:32 (v/v) 2-mercaptoethanol/water.
53. Add 3 µL of 20 mg/mL (286 U/mL) papaine solution and incubate 2 hr at 37°C.
54. Add one drop of glacial acetic acid and lyophilize.
55. Redissolve the sample in 15 µL of 0.2 M ammonium acetate buffer, pH 8.3, and 1
µL of 1:32 (v/v) 2-mercaptoethanol/water.
56. Add 3 µL of 3 mg/mL (72 U/mL) microsomal leucin aminopeptidase solution and
incubate 3 hr at 37°C.
57. Repeat the addition of 3 µL enzyme solution and incubate another 12 hr at 37°C.
58. Add one drop of concentrated acetic acid and lyophilize.
59. Redissolve the sample in 15 µL of 0.1 M ammonium acetate and 0.025 M MnCl2
buffer solution, pH 8.3.
60. Add 3 µL of 5 mg/mL (875 U/mL) prolidase solution and incubate 3 hr at 37°C.
61. Add one drop of concentrated acetic acid and lyophilize.
62. Perform amino acid analysis as described (see Basic Protocol 1, step 13).
SUPPORT
PROTOCOL 6
REDUCTION OF SULFOXIDE-PROTECTED METHIONINE-CONTAINING
NUCLEOPEPTIDES
Additional Materials (also see Basic Protocol 3)
Deprotected crude nucleopeptide (see Basic Protocol 2)
N-Methylmercaptoacetamide
1. Quantitate crude nucleopeptide as described (see Basic Protocol 3, steps 8 to 10).
2. Dissolve 50 OD260 units lyophilized crude nucleopeptide in 1 mL water.
3. Place at 37°C and add a 20- to 100-fold excess (2 to 10 µL) N-methylmercap-
toacetamide. Stir occasionally.






4. After 12 hr, monitor the reaction by reversed-phase C18 HPLC (see Basic Protocol
3, steps 1 to 4).
In general, the methionine-reduced nucleopeptide is eluted after the sulfoxide-containing
nucleopeptide (∼1 to 2 min).
5. If necessary, add more N-methylmercaptoacetamide to achieve complete reduction
within 24 to 36 hr.
6. When complete reduction is achieved, lyophilize and proceed to isolate the desired
reduced nucleopeptide (see Basic Protocol 3, step 6 or 12).
SUPPORT
PROTOCOL 7
DEPROTECTION AND PURIFICATION OF CYSTEINE-CONTAINING
NUCLEOPEPTIDES
Additional Materials (also see Basic Protocol 3)
Nucleopeptide-support (see Basic Protocol 2, step 7)
1 M 1,4-dithiotreitol (DTT) in peroxide-free dioxane (see recipe)
32% ammonium hydroxide
0.05 M ammonium acetate buffer, pH 7.0
20-mL screw-cap pressure tube, O-ring seal preferred





1. Open the synthesis column and transfer the nucleopeptide-support to a 20-mL
screw-cap pressure tube, preferably with an O-ring seal.
2. Add 5 mL of 1 M DTT in peroxide-free dioxane and 5 mL of 32% ammonium
hydroxide, screw the cap on tightly, and incubate 6 to 8 hr at room temperature.
It is necessary to have a large excess of DTT during the ammonia deprotection step to
remove the tert-butylthio protecting group from cysteine and to avoid secondary reactions
such as β-elimination of HS-S-tBu. Dimethylaminomethylene-protected guanosine and
acetyl-protected cytosine phosphoramidites must be used in combination with tert-
butylthio-protected cysteine residues, and cleavage and deprotection must be performed at
room temperature for 6 to 8 hr. Refer to safety recommendations and other notes above
(see Basic Protocol 2).
3. Filter the solution through a disposable polypropylene disposable syringe with a
polyethylene filter or cotton and collect the filtrate in a 50-mL round-bottom flask.
4. Wash the pressure tube three times with MeOH and pass the washes through the
syringe into the same flask.
5. Concentrate the combined solution under reduced pressure (in a rotary evaporator
with a water aspirator) to a volume of ∼2 mL.
Perform gel filtration
6. Set up a purification system as described for MPLC purification (see Basic Protocol
3, step 12), but with a peristaltic pump.
7. Equilibrate a Sephadex G-10 chromatography column with 200 mL of 0.05 M
ammonium acetate buffer, pH 7.0.
8. Dilute the crude nucleopeptide sample with 0.05 M ammonium acetate buffer, pH
7.0, to a volume of 5 mL.






9. Remove the supernatant solution from the column cap position. Introduce the
nucleopeptide sample solution in the column and close.
10. Set the UV detector wavelength at 260 nm with the appropriate lamp and filter. Turn
on the detector and chart recorder. Turn on the peristaltic pump and elute slowly (~1
mL/min) with 0.05 M ammonium acetate buffer, pH 7.0.
Under the conditions described, the nucleopeptide-containing peak is eluted before the
DTT-containing peak. This is because separation is based on molecular weight differences,
with the larger compounds being eluted faster.
11. Observing the chromatogram, select the tubes where the nucleopeptide-containing
peak is eluted and combine eluents. Lyophilize, analyze by HPLC, and purify as
described (see Basic Protocol 3).
It is important to point out that cysteine-containing nucleopeptides may dimerize very
quickly because of oxidation by atmospheric oxygen, yielding a dimer in which two
nucleopeptides are bonded through a disulfide bridge between the peptide chains. When
two or more cysteine residues are present in the nucleopeptide, polymers can be formed.
To prevent oxidation, avoid having samples in solution at room temperature. Keep frozen.
BASIC
PROTOCOL 4
ANALYSIS AND PURIFICATION OF NUCLEOPEPTIDES BY
POLYACRYLAMIDE GEL ELECTROPHORESIS




38% (w/v) acrylamide/2% (w/v) bisacrylamide (see recipe)
10× TBE buffer (1.3 M Tris, 0.45 M boric acid, 25 mM EDTA)





Deprotected crude or purified nucleopeptide (see Basic Protocol 2 or 3)





3 M Tris⋅Cl, pH 8.8 (APPENDIX 2A)
2 M ammonium acetate buffer, pH 7.0
Acetonitrile, HPLC grade
50% (v/v) aqueous methanol (MeOH)
250-mL Erlenmeyer flask
20- and 60-mL syringes
95° and 37°C water baths or heating blocks




Additional reagents and equipment for polyacrylamide electrophoresis (UNIT 10.4
and APPENDIX 3B)







1. Assemble gel plates, spacers, and combs as described in APPENDIX 3B or following
manufacturer’s instructions.
2. In a 250-mL Erlenmeyer flask, combine the following:
12.6 g urea
15 mL 38% (w/v) acrylamide/2% (w/v) bisacrylamide (20% acrylamide)
1.5 mL 10× TBE buffer
30 mL water.
CAUTION: Acrylamide and bisacrylamide are hazardous. Solutions of acrylamide dete-
riorate quickly, especially when exposed to light or left at room temperature (see Reagents
and Solutions).
For oligonucleotides with <25 bases, 20% is the optimum acrylamide concentration (UNIT
10.4).
To speed dissolution of urea, the gel mixture can be heated before adding TEMED and
ammonium persulfate; however, to prevent degradation of acrylamide, do not heat above
55°C. Allow to cool to room temperature before adding TEMED and ammonium persulfate
to prevent polymerization while pouring the gel.
3. Add 300 µL of 10% (w/v) ammonium persulfate and 30 µL TEMED. Mix thoroughly
and wait 30 sec.
4. Gently pull acrylamide solution into a 60-mL syringe, avoiding bubbles, and pour
the gel, allowing it to flow slowly down between the gel plates (see APPENDIX 3B).
5. Insert the comb. Dislodge any trapped air bubbles, especially in the wells, by tapping
gently on the glass plates.
Set up electrophoresis apparatus
6. After the gel has polymerized (usually 30 to 60 min), remove bottom spacer of gel
sandwich and remove extraneous polyacrylamide from around the combs.
7. Fill bottom reservoir of gel apparatus with 0.5× TBE buffer. Place the gel in the
electrophoresis apparatus and clamp plates to support.
8. Pour 0.5× TBE buffer into the upper reservoir to ∼3 cm above the top of the gel. Using
a Pasteur pipet, rinse wells thoroughly with 0.5× TBE buffer to remove stray
fragments of polyacrylamide.
9. Preheat gel ∼1 hr by running at a constant 750 V.
The ideal wattage of the gel should generate enough heat so that the gel plates are warm,
but not too hot to touch.
Load and run the gel
10. To remove urea that has leached into them, flush the sample wells with 0.5× TBE
buffer just prior to loading the gel.
11. Prepare a 5× stock solution with marker dyes:
0.25% (w/v) bromphenol blue
0.25% (w/v) xylene cyanol
30% (w/v) glycerol.
Dilute to 1× with water before loading onto the gel.
In a 20% acrylamide gel, migration of bromphenol blue and xylene cyanol will be similar
to 6-nt and 22-nt linear single-stranded oligonucleotides, respectively.






12. Dissolve each sample of crude or purified nucleopeptide (0.1 to 0.2 OD260 units) in
20 µL of 50% aqueous formamide by vortexing. Microcentrifuge the dissolved
samples briefly to collect them at the bottom of the tube.
13. Heat samples at 95°C in covered microcentrifuge tubes. Place on ice.
14. Load 10 µL sample per well under the surface of the buffer and just above the surface
of the well.
15. Load 5 µL of 1× marker dye solution (step 11).
16. Run gel immediately at 750 V constant voltage. Maintain a constant gel temperature
of ∼65°C. Observe migration of marker dyes to determine electrophoresis time.
Temperatures >65°C can result in cracked plates or smeared bands; temperatures that are
too low can lead to incomplete denaturation.
Process gel
17. Prepare a 10% stock dye solution by dissolving 100 mg Stains-all in 100 mL
formamide. Adjust pH to 7.3 to 7.4 by adding concentrated HCl. Store at 4°C,
protected from light.
18. Mix the following:
10 mL 10% Stains-all solution
10 mL formamide
50 mL isopropanol
1 mL 3 M Tris⋅Cl, pH 8.8
129 mL water.
19. Remove the gel sandwich from the apparatus and carefully place the gel in a shallow
pan containing enough staining solution to cover the gel.
20. Let stand 6 hr to overnight, then decant the stain and gently rinse the gel in water.
If the background is too high, soaking the gel in water and exposing to infrared light can
effect some destaining.
21. Photograph the gel under ambient light against a white background. Alternatively,
dry using a gel dryer (APPENDIX 3B) and scan or photograph.
Purify nucleopeptide by preparative gel electrophoresis
22. Prepare a denaturing polyacrylamide gel as described above and in APPENDIX 3B.
Prepare twice the amount of reagents as required for analytical gel electrophoresis.
23. Load 2 to 8 OD260 units of nucleopeptide in 40 µL of 50% aqueous formamide and
perform electrophoresis.
24. Remove the gel and visualize the nucleopeptide bands using a fluorescent TLC plate
and UV lamp (APPENDIX 3B).
25. Slice the gel on the perimeter of the band with a clean razor blade, and transfer the
fragment to a disposable tube. Crush the fragment with a spatula.
26. Add 3 to 4 mL of 2 M ammonium acetate buffer, pH 7.0, and vortex briefly. Let stand
with vigorous stirring for 12 to 24 hr in a 37°C water bath. Alternatively, freeze and
thaw at least three times to enhance extraction of the product from gel.
27. Mount a Sep-Pak cartridge with a clamp and insert an empty 20-mL syringe on top
of the cartridge.
28. Fill the syringe barrel with 10 mL acetonitrile. Insert and depress the plunger to pass
the solution through the Sep-Pak cartridge over an elapsed time of 15 to 30 sec.






29. Repeat step 28 with 10 mL water and 10 mL of 2 M ammonium acetate buffer, pH
7.0.
30. Remove the syringe and insert a polypropylene syringe fitted with a polyethylene
disc onto the top of Sep-Pak cartridge. Add the 3 to 4 mL buffer and gel (step 26) and
let fluid pass through the column by gravity.
31. Wash the disposable tube (from the gel suspension) with 3 to 4 mL water and add to
the syringe. Repeat wash three more times.
32. Insert a new disposable syringe and elute nucleopeptide with 5 to 7 mL of 50%
MeOH. Collect 1-mL fractions in disposable tubes.
33. Use UV absorbance to identify the fractions where the nucleopeptide has eluted.
Lyophilize and quantify.
REAGENTS AND SOLUTIONS
Use deionized, Milli-Q-purified water (Millipore, 18 mΩ × cm−1) in all recipes and protocol steps, unless
otherwise noted. For common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS
APPENDIX.
Acetonitrile, anhydrous
Reflux and distill over calcium hydride powder under an inert (i.e., N2 or Ar)
atmosphere. Store over calcium hydride lumps under an Ar atmosphere. Prepare
fresh before each use.
Alternatively, DNA-synthesis-grade low-water-content acetonitrile can be purchased and
used as such, or refluxed and distilled from calcium hydride under an inert atmosphere.
Acrylamide/bisacrylamide solution, 38%/2% (w/v)
Dissolve 380 g acrylamide and 20 g bisacrylamide in water to a volume of 1 liter.
Filter through a 0.5-µM membrane. Store 2 to 4 weeks at 4°C,  protected from light.
Activator solution
Prepare 0.8 M sublimed 1H-tetrazole (see recipe) in anhydrous THF (see recipe)
using a septum-sealed distillation collection bulb. For a complete dissolution of
tetrazole, use an ultrasonic bath. Prepare fresh before each use.
Dichloromethane (DCM), anhydrous
Reflux and distill dichloromethane over reagent-grade phosphorus pentoxide under
an inert (N2 or Ar) atmosphere. Store over calcium hydride lumps under Ar
atmosphere. Prepare fresh before each use.
DCM, neutralized
Pass DCM through a basic alumina column in order to eliminate acid traces. Store
up to one week at 20°C.
N,N-Diisopropylethylamine (DIPEA), anhydrous
Place under calcium hydride lumps under an Ar atmosphere for at least one night
before use. Prepare fresh before each use.
Dioxane, peroxide free
Pass dioxane through a basic alumina column in order to eliminate all traces of
peroxide. Store until a positive peroxide test is obtained (mix equal volumes of 5%
(w/v) KI aqueous solution and dioxane).
A yellowish color indicates the presence of peroxides. No yellowish color should be observed
if the solvent is peroxide-free.







Dissolve 40 g phenol in 10 mL absolute EtOH. Mix 2 mL of 2 mM potassium cyanide
and 100 mL pyridine freshly distilled over ninhydrin. Mix each solution separately
with 4 g Amberlite MB-3 resin (Merck) for 45 min. Filter and mix both solutions
together to obtain the desired reagent A. Store up to 1 to 2 years at 4°C.
Ninhydrin reagent B
Dissolve 2.5 g ninhydrin in 50 mL absolute EtOH. Keep the solution protected from
light in an amber glass container (up to 1 to 2 years at 4°C).
Oxidizer solution
Dilute 5.0 to 6.0 M anhydrous tert-butylhydroperoxide in decane (Aldrich or Fluka)
to a final concentration of 1 M in anhydrous DCM (see recipe). Prepare fresh before
each use.
Pyridine, anhydrous
Reflux and distill pyridine over reagent-ninhydrin powder under an inert (i.e., N2 or
Ar) atmosphere. Reflux and distill again over calcium hydride powder. Place over
calcium hydride lumps under an Ar atmosphere. Prepare fresh before each use.
Tetrahydrofuran (THF), anhydrous
Dry peroxide-free tetrahydrofuran (see recipe) by continuous reflux and distillation
over sodium metal and benzophenone under inert atmosphere until purple color
persists. Prepare fresh before each use.
THF, peroxide free
Pass THF through a basic alumina column in order to eliminate peroxides. Store
until a positive test is obtained (see peroxide-free dioxane). Protect from light.
1H-Tetrazole, sublimed
Transfer a commercial solution of 1H-tetrazole in acetonitrile into a round-bottom
flask (this can be mixed with unused wet solutions of tetrazole from the DNA
synthesizer). Evaporate to dryness under reduced pressure using a rotary evaporator
with a water aspirator. Use a sublimation apparatus to sublime the remaining solid
to obtain pure crystalline 1H-tetrazole. Store under Ar up to 5 years at ambient
temperature.
CAUTION: 1H-Tetrazole is an explosive compound. Never heat near the melting point
(157°-159°C). Wear safety glasses and gloves during sublimation procedure. Manipulate
with caution in a well-ventilated fume hood.
1H-Tetrazole is no longer commercially available in solid form. Solutions of 1H-tetrazole
in acetonitrile may be purchased from typical organic chemical suppliers such as Aldrich.
COMMENTARY
Background Information
The methodologies for the preparation of
various kinds of peptide-oligonucleotide con-
jugates have been reviewed by different authors
(Tung and Stein, 2000; Zubin et al., 2002; UNIT
4.5). The research published since the last review
report on adaptations, modifications, problems,
or improvements of previously described meth-
ods (e.g., Chen et al., 2002, 2003; Drioli et al.,
2002; Kachalova et al., 2002; Viladkar, 2002;
Zatsepin et al., 2002), but no new synthesis
design has been described. For these reasons,
as well as for space limitations, only a few
comments on the preparation of nucleopeptides
and on the use of stepwise solid-phase method-
ology to obtain peptide-oligonucleotide conju-
gates will be made here (i.e., only repre-
sentative examples will be cited).
All the methodologies used to prepare hy-
brids in which the two components are directly
linked through phosphate diesters (here re-
ferred to as nucleopeptides) share a common
outline: the key linking phosphodiester bond is






created having all the nonparticipating func-
tional groups protected.
This key phosphate has been formed using
different chemistries that yield phosphodiester
bonds, namely the phosphate triester (Kuyl-Ye-
heskiely et al., 1989; Ueno et al., 1993), the
H-phosphonate (Kuyl-Yeheskiely et al., 1987),
and the phosphite triester (Dreef-Tromp et al.,
1992a; Sakakura and Hayakawa, 2000; De-
béthune et al., 2002a; Jeyaraj et al., 2002) ap-
proaches. Synthesis of nucleopeptides has been
carried out in solution and on solid supports,
both by convergent (Dreef-Tromp et al., 1992a;
Robles et al., 1995; Sakakura and Hayakawa,
2000) and stepwise strategies (Debéthune et al.,
2002a). Protection schemes have included a
large variety of permanent protecting groups
that are either chemically or enzymatically
(Flohr et al., 1999) removable.
Many nucleopeptides have been prepared
since the pioneering work of Z.A. Shabarova
in the sixties (Shabarova, 1970). In 1992, van
Boom’s group was able to obtain a nucleopep-
tide with up to ten nucleosides (Dreef-Tromp
et al., 1992a) and two trifunctional amino acids
besides the linking residue. The methodology
described here has allowed the synthesis of
nucleopeptides containing up to five amino
acids with functionalized side chains (besides
the linking residue), and to obtain a nucleopep-
tide with thirteen amino acids and fifteen nu-
cleosides.
In the authors’ opinion, one of the main
advantages of this stepwise solid-phase meth-
odology is that it circumvents the need to ma-
nipulate protected peptides. These are often
highly insoluble in most organic solvents,
which renders both the purification and the
phosphitylation (or phosphorylation) difficult.
Moreover, most of the monomers required
can be purchased from commercial suppliers.
Besides the trifunctional amino acid derivatives
whose synthesis is described here, the only
nucleoside synthons that should have to be
synthesized in the laboratory are the 5′-phos-
phoramidites of 2′-deoxycytidine and 2′-de-
oxyguanosine. The commercially available 5′-
phosphoramidites of these nucleosides are only
suitable for the preparation of nucleopeptides
with 5′-oligonucleotide-homoserine or tyro-
sine linkages, and their standard nucleobase-
protecting groups are not compatible with base-
labile nucleopeptides.
Finally, it is worth emphasizing that com-
pared to other methods the use of an amino acid
to attach the two moieties has the advantage of
allowing one to place the linking unit at any
position in the peptide chain, with no need to
prepare a specially designed support. The only
exception to this assertion, as previously men-
tioned, is that homoserine cannot be placed at
the C-terminal position. The acid treatment that
removes the Boc group simultaneously elimi-
nates its DMTr hydroxyl-protecting group, and
the propensity for homoserine to lactonize
would easily provoke cleavage of the peptide-
resin bond, resulting in loss of peptide chains.
As previously stated, peptide-oligonu-
cleotide conjugates that are not directly linked
or are linked through amide bonds have also
been synthesized using stepwise procedures. In
most cases, hybrids have been assembled onto
insoluble matrices, but the modifiable solubil-
ity of polyethylene glycol has also been ex-
ploited (Drioli et al., 2002). Peptide assembly
is more often carried out first, but synthesis
starting with oligonucleotide elongation has
also been reported (Bergmann and Bannwarth,
1995; Sarracino et al., 1998). In general, there
is no need for concern about the stability of the
linkage between the two moieties, but some
degradation of the target molecule during the
final deprotection treatment has been found to
be associated with the use of immobilized tri-
functional linkers (Basu and Wicsktrom, 1995).
It is important to note that the protection
scheme proposed here for the preparation of
nucleopeptides is of general application and
can be extended to the synthesis of any peptide-
oligonucleotide conjugate. In addition, when
the target molecule contains trifunctional
amino acids that may suffer side reactions,
and/or base-labile linkers are used for their
assembly, the recommendation to use the most
labile set of permanent protecting groups also
applies.
The most common applications of peptide-
oligonucleotide conjugates have been dis-
cussed earlier (see unit introduction). Such
molecules can also find application in structural
studies (Ho et al., 1999; Gómez-Pinto et al.,
2003), in studies on the structural requirements
of an enzyme (Debéthune et al., 2002b), or in
studies on the behavior of metal complexes
(Civitello et al., 2001; Marchán et al., 2001).
Hopefully, access to user-friendly synthesis
procedures and the future development of
newer, more convenient procedures will inspire
an increasing number of laboratories to prepare
more conjugates, and thus enlarge their fields
of application.







As previously pointed out, the most critical
point in nucleopeptide synthesis is the choice
of protecting groups, which must be accompa-
nied by appropriate selection of the final depro-
tection conditions (see Strategic Planning and
Table 4.22.1).
It is also important to ensure that oligonu-
cleotide elongation is carried out on a homoge-
neous immobilized peptide. The amino acid
composition should be checked before the oli-
gonucleotide synthesis is begun. Depending on
the peptide length and composition, HPLC and
MS analysis of the crude product obtained after
deprotection of an aliquot of peptide-resin may
also be worthwhile.
If large nucleopeptides or conjugates are to
be prepared, leaving the DMTr group after
incorporation of the last nucleoside synthon
may facilitate the HPLC analysis and purifica-
tion of the crude product. Two purification runs,
both by HPLC or by combining HPLC and
PAGE, may sometimes be required.
Troubleshooting
Large nucleopeptides, especially depending
on the amino acid composition, may show com-
plex HPLC profiles. HPLC analysis at higher
temperature (50° to 55°C) may reduce confor-
mational equilibria, and in some cases simplify
the HPLC profile of the crude product. As
previously suggested, analysis by PAGE under
denaturing conditions may also be a good al-
ternative.
Anticipated Results
If peptide elongation has proceeded satis-
factorily, the expected peptide should be the
major peak in the crude nucleopeptide after
cleavage and deprotection.
The coupling yield of the first nucleoside
phosphoramidite is variable, with an average
value of 70%. Nearly quantitative yields, as in
any other oligonucleotide synthesis, are ob-
tained in the subsequent couplings.
The cleavage yield with concentrated am-
monia/dioxane treatment at 55°C usually
ranges from 60% to 80%. An additional treat-
ment with TBAF, if allowed by the nucleopep-
tide structure, leaves <5% of the nucleopeptide
on the resin.
The purity of the crude nucleopeptide varies
depending on the nucleopeptide size and com-
position. In the HPLC profiles shown in Figure
4.22.9, the main peak (expected product) ac-
counts for ∼75% of the total area in the case of
the tryptophan-containing nucleopeptide, and
∼60% in the arginine-containing one. MALDI-
TOF-MS analysis of the crude sample allows
confirmation that it contains the target product.
Purification can usually be accomplished in
a single run by either reversed-phase MPLC or
HPLC on semipreparative C18 columns.
Overall yields (nucleopeptide assembly, de-
protection, and purification) will also vary de-
pending on the homogeneity of the crude prod-
uct and whether purification requires one or two
steps. The arginine-containing nucleopeptide,
for instance, is an example of a nucleopeptide
of medium difficulty, and was obtained in 17%
yield.
Time Considerations
The preparation of nucleopeptides using these
procedures may be a time-demanding task if








Figure 4.22.9 Examples of HPLC profiles of nucleopeptides: (A) crude and (B) purified Ac-Lys-Trp-Lys-Hse(p3′dG-
CATCG)-Ala-OH, and (C) crude and (D) purified Ac-Tyr(p3′dTTTCAGAAAATCTAG)-Leu-Asp-Pro-Arg-Ile-Thr-Val-OH. See
Basic Protocol 3 for gradient conditions, eluents, and column employed.






the handle linking the hybrid molecule to the
resin, have to be prepared. With all of the
precursors, reagents, and solutions in hand, the
synthesis and purification of a nucleopeptide
containing ten amino acids and a 10-mer oli-
gonucleotide can be accomplished in ∼3 weeks,
depending, for instance, on the availability of
techniques such as amino acid analysis to assess
that correct yields have been obtained, or on
whether peptide purity is checked before pro-
ceeding with oligonucleotide elongation. The
time required to purify the target molecule may
vary depending on the scale of synthesis and,
obviously, the quality of the crude product. A
tentative schedule would be the following:
Week 1: Preparation of solid support, manual
synthesis of peptide chain, and analysis of pep-
tide-resin.
Week 2: Oligonucleotide elongation, depro-
tection and cleavage, and analysis of the crude
nucleopeptide to set up the purification condi-
tions.
Week 3: Purification of the nucleopeptide and
full characterization of the product (amino acid
analysis after acid hydrolysis or enzymatic di-
gestion, determination of the relative propor-
tion of nucleosides after enzymatic digestion,
and mass spectrometric analysis).
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